var title_f1_37_1616="Dorsalis pedis artery puncture";
var content_f1_37_1616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Cannulation of dorsalis pedis artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Technique of cannulation of the dorsalis pedis artery. Before placement of a catheter in this artery, adequacy of collateral flow should be demonstrated. The artery should be occluded by pressure, and the great toe should be blanched by compression of the toenail for several seconds. While the dorsalis pedis artery is still being compressed, color should return rapidly to the toe after pressure on the nail is released.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1616=[""].join("\n");
var outline_f1_37_1616=null;
var title_f1_37_1617="Augmented urethroplasty";
var content_f1_37_1617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Augmented urethroplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1617=[""].join("\n");
var outline_f1_37_1617=null;
var title_f1_37_1618="Gallstone ileus on computed tomography of the abdomen";
var content_f1_37_1618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Gallstone ileus seen on computed tomography (CT) scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan in a 75-year-old woman with small bowel obstruction due to gallstone ileus. Left panel: Free air is seen in the biliary tree and gallbladder (arrow). Right panel: Dilated loops of small bowel with large gallstone with a calcified rim (arrow) impacted in the terminal ileum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nezam Afdhal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1618=[""].join("\n");
var outline_f1_37_1618=null;
var title_f1_37_1619="Perforating folliculitis - close view";
var content_f1_37_1619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforating folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules with central hyperkeratosis were present on the extremities of this woman with perforating folliculitis and renal failure. Perforating folliculitis most often occurs in the setting of renal failure or diabetes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Patrick Keehan, D.O. and Greg Hosler, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1619=[""].join("\n");
var outline_f1_37_1619=null;
var title_f1_37_1620="Eye muscles";
var content_f1_37_1620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extraocular muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 421px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Each eye has six extraocular muscles, which are yoked in pairs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lavin, PJM. Eye movement disorders and diplopia. In: Neurology in Clinical Practice: Principles of Diagnosis and Management, 2nd ed, Bradley, WG (Ed), Butterworth-Heinemann, Boston 1996. p. 185. Copyright &copy; 1996 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1620=[""].join("\n");
var outline_f1_37_1620=null;
var title_f1_37_1621="Insulin regular: Patient drug information";
var content_f1_37_1621=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Insulin regular: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     see \"Insulin regular: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=see_link\">",
"     see \"Insulin regular: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2105104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumuLIN&reg; R;",
"     </li>",
"     <li>",
"      HumuLIN&reg; R U-500;",
"     </li>",
"     <li>",
"      NovoLIN&reg; R",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2104962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humulin&reg; R;",
"     </li>",
"     <li>",
"      Novolin&reg; ge Toronto",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to insulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep workouts the same. More workouts may lower your insulin needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use out dated insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give a missed shot as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next shot, skip the missed shot and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened containers in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3528085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store opened vials at room temperature or in a refrigerator. If stored at room temperature, throw away any part not used after 4 or 6 weeks as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699511",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened cartridges and prefilled syringes at room temperature. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11771 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1621=[""].join("\n");
var outline_f1_37_1621=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105104\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104962\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018601\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018600\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018605\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018606\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018608\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018603\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018604\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018609\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018610\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=related_link\">",
"      Insulin regular: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/44/36551?source=related_link\">",
"      Insulin regular: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_37_1622="Cyanocobalamin (vitamin B12): Pediatric drug information";
var content_f1_37_1622=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyanocobalamin (vitamin B12): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/10/28838?source=see_link\">",
"    see \"Cyanocobalamin (vitamin B12): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/16/35077?source=see_link\">",
"    see \"Cyanocobalamin (vitamin B12): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ener-B&reg; [OTC];",
"     </li>",
"     <li>",
"      Nascobal&reg;;",
"     </li>",
"     <li>",
"      Twelve Resin-K [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Water Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral, sublingual: 0.4 mcg/day (~0.05 mcg/kg/day);",
"     <b>",
"      Note:",
"     </b>",
"     Neonates born to vegan mothers should be supplemented with the AI for vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     from birth; they may have low vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     stores at birth and, if breast-feeding, may only receive a small amount of the vitamin from the mother's milk (Mangels, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anemia of prematurity:",
"     </b>",
"     I.M.: Limited data available; 100 mcg once monthly for 4 months with concomitant folic acid administration produced higher hemoglobin in 34 preterm neonates (GA &lt;36 weeks; birth weight &lt;1800 g) when compared to placebo or folate monotherapy; all patients received vitamin E and iron supplementation (Worthington-White, 1994).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pernicious anemia; treatment of deficiency:",
"     </b>",
"     Limited data available: I.M., SubQ: Initial: 1000 mcg/day for 2-7 days based upon clinical response; maintenance: 100 mcg/month;",
"     <b>",
"      Note:",
"     </b>",
"     For severe anemia, a lower initial dose of 0.2 mcg/kg/dose for 2 days followed by  the above regimen has been recommended due to potential hypokalemia observed during initial treatment of adults with severe anemia; additional potassium supplementation may also be required (Rasmussen, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/10/28838?source=see_link\">",
"      see \"Cyanocobalamin (vitamin B12): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral, sublingual:",
"     <b>",
"      Note:",
"     </b>",
"     Neonates born to vegan mothers should be supplemented with the AI for vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     from birth; they may have low vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     stores at birth and, if breast-feeding, may only receive a small amount of the vitamin from the mother's milk (Mangels, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 1-6 months: 0.4 mcg/day (0.05 mcg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 7-12 months: 0.5 mcg/day (0.05 mcg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral, Sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1-3 years: 0.9 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     4-8 years: 1.2 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     9-13 years: 1.8 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;14 years: 2.4 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pernicious anemia:",
"     </b>",
"     Limited data available: I.M., SubQ: Initial: 1000 mcg/day for 2-7 days based upon clinical response; maintenance: 100 mcg/month; for severe anemia, a lower initial dose of 0.2 mcg/kg/dose for 2 days followed by the above regimen has been recommended; initial low dosage recommended due to potential hypokalemia observed during initial treatment of adults with severe anemia (Rasmussen, 2001). Concurrent folic acid supplementation may also be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      deficiency:",
"     </b>",
"     Dosing regimens variable: I.M., SubQ: 1000 mcg/day for 2-7 days based upon clinical response followed by 100 mcg/week for a month; for severe deficiency, a lower initial dose of 0.2 mcg/kg/dose for 2 days followed by  the above regimen has been recommended due to potential hypokalemia observed during initial treatment of adults with severe anemia; additional potassium supplementation may also be required (Rasmussen, 2001); for malabsorptive causes of B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency, monthly maintenance doses of 100 mcg have been recommended or as an alternative 100 mcg/day for 10-15 days (total dose of 1-1.5 mg), then  once or twice weekly for several months; may taper to 60 mcg every month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Recommended intake:",
"     </b>",
"     2.4 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnancy: 2.6 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactation: 2.8 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pernicious anemia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: I.M., deep SubQ: 100 mcg/day for 6-7 days; if improvement, give same dose on alternate days for 7 doses; then every 3-4 days for 2-3 weeks; once hematologic values have returned to normal, maintenance dosage: 100 mcg/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing: I.M., deep SubQ: Initial: 1000 mcg/day for 5 days followed by 500-1000 mcg/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hematologic remission (without evidence of nervous system involvement):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.M., SubQ: 100-1000 mcg/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intranasal (Nascobal&reg;): 500 mcg (1 spray) in one nostril once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 1000-2000 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      deficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.M., deep SubQ: Initial: 30 mcg/day for 5-10 days; maintenance: 100-200 mcg monthly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intranasal (Nascobal&reg;): 500 mcg (1 spray) in one nostril once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 250 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1000 mcg/mL (1 mL, 10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral: 50 mcg (100s); 100 mcg (100s); 250 mcg (100s, 250s); 500 mcg (100s, 250s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, sublingual: 500 mcg (100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nascobal&reg;: 500 mcg/spray (2.3 mL) [contains benzalkonium chloride; delivers 8 doses]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, for buccal application/oral/sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twelve Resin-K: 1000 mcg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mcg, 100 mcg, 250 mcg, 500 mcg, 1000 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ener-B&reg;: 100 mcg, 500 mcg, 1000 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual: 1000 mcg, 2500 mcg, 5000 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral: 1000 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ener-B&reg;: 1500 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes nasal spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Nascobal&reg; nasal spray: Prior to initial dose, activate (prime) spray nozzle by pumping unit quickly and firmly until first appearance of spray, then prime twice more. The unit must be reprimed once immediately before each use. Administer at least one hour before or after ingestion of hot foods or liquids; hot foods can cause nasal secretions and a resulting loss of medication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Not generally recommended for treatment of severe vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency due to poor oral absorption (lack of intrinsic factor); oral administration may be used in less severe deficiencies and maintenance therapy; may be administered without regard to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.M. or deep SubQ: Avoid I.V. administration due to a more rapid system elimination with resulting decreased utilization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sublingual: Place under the tongue and allow to dissolve; do not swallow whole, chew, or crush",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F155186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pernicious anemia; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency due to dietary deficiencies or malabsorption diseases; inadequate secretion of intrinsic factor, inadequate utilization of B",
"     <sub>",
"      12",
"     </sub>",
"     (eg, during neoplastic treatment); increased B",
"     <sub>",
"      12",
"     </sub>",
"     requirements due to pregnancy, thyrotoxicosis, hemorrhage, malignancy, liver or kidney disease; nutritional supplement",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F155185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: CHF, peripheral vascular disorder, peripheral vascular thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, headache, hypoesthesia, incoordination, pain, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, urticaria, exanthema (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia, glossitis, nausea, sore throat, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Polycythemia vera",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, arthritis, back pain, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (parenteral) and infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyanocobalamin, any component, or cobalt; patients with hereditary optic nerve atrophy (Leber's disease)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium concentrations and platelet counts should be monitored early as severe hypokalemia (sometimes fatal) and thrombocytosis have occurred after the conversion of megaloblastic anemia to normal erythropoiesis; an intradermal test dose of parenteral cyanocobalamin is recommended before initiating the nasal spray in patients suspected to be sensitive to cyanocobalamin. Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency masks signs of polycythemia vera; use caution in other conditions where folic acid or vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     administration alone might mask true diagnosis despite hematologic response. The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Only I.M./SubQ routes are used to treat pernicious anemia; oral and intranasal administration are not indicated until hematologic remission and there are no signs of nervous system involvement. Avoid the I.V. route as it has been associated with anaphylaxis. Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency for &gt;3 months results in irreversible degenerative CNS lesions; neurologic manifestations will not be prevented with folic acid unless vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     is also given; spinal cord degeneration might also occur when folic acid is used as a substitute for vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     in anemia prevention. Vegetarian diets may result in vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection may contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of benzyl alcohol containing injections in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Intranasal therapy is only for use in patients who are in remission following injectable treatment. Efficacy of intranasal treatment in patients with nasal pathology or with other concomitant intranasal therapy has not been determined. Patients with early Leber&rsquo;s disease (hereditary optic nerve atrophy) who were treated with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     suffered severe and swift optic atrophy. These patients should not receive cyanocobalamin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May diminish the therapeutic effect of Cyanocobalamin. The expected hematologic response for the treatment of anemia may be opposed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14207663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Water soluble vitamins cross the placenta. Absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     may increase during pregnancy. Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     requirements may be increased in pregnant women compared to nonpregnant women. Serum concentrations of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     are higher in the neonate at birth than the mother (IOM, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium (particularly during initial treatment of deficiency), erythrocyte and reticulocyte count, hemoglobin, hematocrit, platelets, serum cyanocobalamin and folate concentrations; methylmalonate (MMA) and total homocysteine (elevated in Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1057485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     levels: Normal: &gt;300 pg/mL; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency: &lt;200 pg/mL (200-300 pg/mL borderline result, possible deficiency); megaloblastic anemia: &lt;100 pg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis, used in cell replication and hematopoiesis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Megaloblastic anemia: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conversion of megaloblastic to normoblastic erythroid hyperplasia within bone marrow: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Increased reticulocytes: 2-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Complicated vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency: I.M., SubQ: Resolution of:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Psychiatric sequelae: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombocytopenia: 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Granulocytopenia: 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Drug is absorbed from the terminal ileum in the presence of calcium; for absorption to occur, gastric &ldquo;intrinsic factor&rdquo; must be present to transfer the compound across the intestinal mucosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Principally stored in the liver, also stored in the kidneys and adrenals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Bound to transcobalamin II",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted in the tissues to active coenzymes methylcobalamin and deoxyadenosylcobalamin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Pernicious anemia: 1.2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal gel: 8.9% (relative to I.M. formulation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal spray: Nascobal&reg;: 6.1% (relative to I.M. formulation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., SubQ: 30 minutes to 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: 1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 50% to 98% unchanged in the urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Department Health and Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      <sub>",
"       6",
"      </sub>",
"      , Folate, Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      , Pantothenic Acid, Biotin, and Choline,\" (Chapter 9) available at",
"      <a href=\"file://books.nap.edu/openbook/0309065542/html/306.html\" target=\"_blank\">",
"       file://books.nap.edu/openbook/0309065542/html/306.html",
"      </a>",
"      . Last accessed February 22, 2005.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lane LA and Rojas-Fernandez C, &ldquo;Treatment of Vitamin B(12)-Deficiency Anemia: Oral Versus Parenteral Therapy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(7):1268-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/37/1622/abstract-text/12086562/pubmed\" id=\"12086562\" target=\"_blank\">",
"        12086562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mangels AR and Messina V, \"Considerations in Planning Vegan Diets: Infants,\"",
"      <i>",
"       J Am Diet Assoc",
"      </i>",
"      , 2001, 101(6):670-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/37/1622/abstract-text/11424546/pubmed\" id=\"11424546\" target=\"_blank\">",
"        11424546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rasmussen SA, Fernhoff PM, and Scanlon KS, &ldquo;Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      Deficiency in Children and Adolescents,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1):10-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/37/1622/abstract-text/11148506/pubmed\" id=\"11148506\" target=\"_blank\">",
"        11148506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Worthington-White DA, Behnke M, and Gross S, \"Premature Infants Require Additional Folate and Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      to Reduce the Severity of the Anemia of Prematurity,\"",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 1994, 60(6):930-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/37/1622/abstract-text/7985636/pubmed\" id=\"7985636\" target=\"_blank\">",
"        7985636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13187 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1622=[""].join("\n");
var outline_f1_37_1622=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057483\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442273\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057477\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155113\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155098\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057487\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155186\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057480\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057486\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155185\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057491\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057476\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057475\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299104\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155106\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207663\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057482\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057485\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057474\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057489\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057490\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13187|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/10/28838?source=related_link\">",
"      Cyanocobalamin (vitamin B12): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/16/35077?source=related_link\">",
"      Cyanocobalamin (vitamin B12): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_37_1623="Scimitar syndrome II";
var content_f1_37_1623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73397%7EPULM%2F53382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73397%7EPULM%2F53382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scimitar syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows an abnormal right basilar draining vein as well as dilated central pulmonary arteries due to pulmonary arterial hypertension from longstanding left-to-right shunt.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scimitar syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An angiogram (venous phase) demonstrates the aberrant right pulmonary vein draining part of the right lung to the inferior vena cava.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1623=[""].join("\n");
var outline_f1_37_1623=null;
var title_f1_37_1624="Diagnosis and treatment of Ebola and Marburg hemorrhagic fever";
var content_f1_37_1624=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of Ebola and Marburg hemorrhagic fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1624/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1624/contributors\">",
"     Mike Bray, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1624/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1624/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1624/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1624/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/37/1624/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The filoviruses, Marburg and Ebola, are among the most virulent pathogens of humans, causing severe hemorrhagic fever that resembles fulminant septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/1\">",
"     1",
"    </a>",
"    ]. Case fatality rates in epidemics in central Africa, including an outbreak of Marburg hemorrhagic fever in Angola in 2005, have reached 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/2\">",
"     2",
"    </a>",
"    ]. Most infections have arisen out of unsuspected exposure to an animal reservoir or direct physical contact with the body fluids of a sick patient. However, there are also concerns about the use of these pathogens as agents of bioterrorism.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of Ebola and Marburg viruses will be reviewed here. The epidemiology, pathogenesis, and clinical manifestations of these pathogens are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/16/19721?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOTERRORISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their virulence, stability, and high infectivity as small-particle aerosols, Marburg and Ebola virus are classified as Category A bioterror agents by the Centers for Disease Control and Prevention (CDC) and the National Institute of Allergy and Infectious Diseases (NIAID) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The occurrence of even a single human infection outside of Africa is therefore a public health emergency requiring immediate investigation, since it could represent the leading edge of an impending outbreak.",
"   </p>",
"   <p>",
"    Marburg and Ebola hemorrhagic fever occur naturally only in central Africa. The first challenge for a physician called to treat an unrecognized case outside that region would therefore be to consider the possibility of filovirus infection as part of the differential diagnosis of an acutely ill patient. In the case of a single sick individual, the doctor would be unlikely to suspect such a cause of illness, both because of the extreme improbability of observing Marburg or Ebola virus infection outside their endemic regions, and because the initial signs and symptoms of filoviral infection resemble those of many other acute infectious processes, including other types of viral hemorrhagic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/16/19721?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, the simultaneous appearance of many severely ill patients with similar signs and symptoms would alert clinicians to the possibility of a bioterror attack and thereby increase suspicion of an \"exotic\" illness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/7\">",
"     7",
"    </a>",
"    ]. However, recognition of an attack may be significantly delayed if infected individuals disperse widely after exposure and become ill in different geographic locations. Such a pattern would be expected if an aerosolized agent was released in an airport or train station.",
"   </p>",
"   <p>",
"    Once the epidemiologic picture begins to suggest bioterrorism, the clinician must alert the hospital administration and local public health authorities, who will in turn inform state and national agencies of the situation. Efforts to identify the infectious agent, track those exposed, and manage the outbreak will then become a joint effort among multiple agencies. General concepts regarding bioterrorism are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Suspected bioterrorism'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even though there is no specific therapy for Marburg or Ebola hemorrhagic fever, it is still important to make the diagnosis as early as possible, so as to initiate supportive measures before the development of irreversible shock, alert public health authorities, and institute infection control procedures.",
"   </p>",
"   <p>",
"    Whether filoviral hemorrhagic fever is initially considered in the differential diagnosis will vary markedly with the circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high suspicion of exposure would be prompted by history of a laboratory accident in a filovirus researcher or illness in a health care worker during an epidemic in Africa.",
"     </li>",
"     <li>",
"      A more challenging situation is the evaluation of an acutely ill traveler who has recently been in a region in central Africa where filovirus outbreaks have occurred, but does not recall any contact with a patient or exposure to a possible reservoir animal.",
"     </li>",
"     <li>",
"      By far the most difficult problem is the recognition of Ebola or Marburg hemorrhagic fever resulting from a clandestine bioterror attack, since diagnosis will not be aided by a history of recent travel or exposure to a known source of infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bioterrorism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these scenarios is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory or health care worker",
"    </span>",
"    &nbsp;&mdash;&nbsp;The case of an accidentally infected laboratory investigator or member of an outbreak response team is a unique situation, since the affected individual will probably be able to name the pathogen and the time and route of exposure. In addition, a protocol from the individual's home agency may already be in place detailing case management, including the use of rapid diagnostic tests to monitor blood samples.",
"   </p>",
"   <p>",
"    If medical care is sought early in the incubation period, the patient and his colleagues may express strong interest in making use of experimental forms of postexposure prophylaxis that have shown some degree of efficacy in nonhuman primates (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Patient management'",
"    </a>",
"    below). This question should be referred to experts in the filovirus field, including the staff of the CDC Special Pathogens Branch and the US Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick in Maryland (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Additional resources and contact information'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Traveler from central Africa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute onset of febrile illness in a person who has been in central Africa presents a difficult diagnostic problem, because of the plethora of infectious diseases in that region, including other types of viral hemorrhagic fever, such as yellow fever. Unless there is a history of direct physical contact with a person with Marburg or Ebola hemorrhagic fever, exposure to a sick chimpanzee or gorilla, or visit to a bat-infested cave during the previous two to three weeks, the patient will most likely have a more common illness, such as malaria or one of a variety of bacterial infections, including typhoid fever [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/8\">",
"     8",
"    </a>",
"    ]. It is therefore essential to begin the diagnostic work-up by obtaining a detailed travel history and screening for treatable diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=see_link\">",
"     \"Evaluation of fever in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Suspected bioterrorism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The index case in a bioterror attack with a filovirus would most likely be a previously healthy individual who abruptly develops fever and signs of severe systemic illness. Making the correct diagnosis under these circumstances would be extremely challenging, since the differential diagnosis would include various forms of bacterial sepsis (staphylococcal or streptococcal infection, gram-negative sepsis, toxic shock syndrome, or meningococcemia), typhoid fever and other forms of Salmonella or Shigella infection, leptospirosis, psittacosis, dengue, hantavirus pulmonary syndrome, rubella, severe varicella or measles, malaria, severe dengue, and other types of viral hemorrhagic fever. The absence of recent foreign travel would help to eliminate some of these diagnoses (eg, malaria), but others could only be ruled out by performing blood cultures or other laboratory tests.",
"   </p>",
"   <p>",
"    In the event of a large-scale bioterror attack, increasing numbers of severely ill patients with similar signs and symptoms would begin to appear in medical facilities. These events would most likely prompt physicians to consider the possibility of a deliberate attack with a biological weapon, and the differential diagnosis would then shift to infections caused by agents on the CDC bioterrorism list [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once potential biological weapons are being considered as the causative agents of the patient's disease, the differential diagnosis can be somewhat simplified by considering certain basic features of illness. For example, if patients do not display specific localizing signs of infection, such as pneumonia, the diagnostic effort may focus on viral hemorrhagic fever and other generalized systemic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Imaging'",
"    </a>",
"    below). Viral hemorrhagic fever becomes a more likely diagnosis if a previously healthy individual becomes abruptly ill with the following signs and symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High fever, sometimes with relative bradycardia",
"     </li>",
"     <li>",
"      Severe malaise with muscle and joint pains",
"     </li>",
"     <li>",
"      Conjunctival petechiae and easy bruising",
"     </li>",
"     <li>",
"      Confusion and obtundation in the absence of localizing neurological signs or evidence of central nervous system infection",
"     </li>",
"     <li>",
"      Early onset of a \"capillary leak syndrome\", with rapid progression to hypotension, shock, and multiorgan failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a variety of types of viral hemorrhagic fever can display marked flushing of the skin or an erythematous rash, but the presence of a nonpruritic maculopapular eruption on the upper body may help to focus suspicion on filovirus infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/16/19721?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory studies supportive of the diagnosis of Marburg or Ebola virus infection include thrombocytopenia and the presence of disseminated intravascular coagulation (DIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. However, since bacterial agents such as Yersinia pestis and a number of other pathogens, including the agents of other types of viral hemorrhagic fever, also induce severe coagulopathy with DIC, these findings are nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data regarding the radiographic features of viral hemorrhagic fevers in humans or animals. However, the results of necropsy studies in nonhuman primates suggest that introduction of an aerosolized filovirus into the respiratory tract is unlikely to cause discrete lesions that will produce focal abnormalities on chest X-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/13\">",
"     13",
"    </a>",
"    ]. This is in contrast to the pulmonary infiltrates characteristic of airborne infection by the agents of plague and tularemia, or changes in the mediastinum typical of anthrax. Thus, the presence of pulmonary infiltrates might suggest an alternative diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rapid diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid diagnostic tests for Marburg and Ebola virus infection have been developed, based on the detection in blood or other body fluids of viral antigens by enzyme-linked immunosorbent assay (ELISA) or specific RNA sequences by reverse-transcription polymerase chain reaction (RT-PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Data from African outbreaks and from experiments in laboratory animals indicate that all persons who have become ill will test positive by such assays, but it is not known whether these tests are sensitive enough to detect individuals who are still incubating the virus.",
"   </p>",
"   <p>",
"    Such tests are performed only in specialized laboratories, including CDC and USAMRIID. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Additional resources and contact information'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirming the diagnosis of Marburg or Ebola hemorrhagic fever relies on replication of the causative agent in cell culture (in a BSL-4 containment laboratory) and visualization of the characteristic viral particles by electron microscopy. In the United States, such tests are currently performed only by the CDC and USAMRIID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sample handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the early stages of the workup, when Ebola or Marburg hemorrhagic fever are only one of many possible diagnoses, specimens for laboratory testing may be labeled, transported, and tested according to recommendations by the CDC for blood-borne pathogens. If additional information begins to suggest a diagnosis of filovirus infection, physicians wishing to obtain assistance from special laboratories must first report the suspected case to their local public health agencies. Patient samples must not be shipped to national reference centers before consulting directly with those who will receive the material. Arrangement for such testing is initiated by alerting the hospital infection control office and local public health authorities, who will, in turn, contact the national laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATIENT MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific therapy is available for patients who have developed Ebola or Marburg hemorrhagic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/18\">",
"     18",
"    </a>",
"    ]. The antiviral drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , which inhibits some other RNA viruses, is ineffective against these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/19\">",
"     19",
"    </a>",
"    ]. Care is therefore supportive [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/8,20\">",
"     8,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the manifestations of filoviral hemorrhagic fever are caused principally by host responses to infection, supportive care should focus on maintaining circulatory function and blood pressure, correction of severe coagulopathy, and other measures to keep the patient alive while the immune system mobilizes the antigen-specific immune responses needed to eliminate the pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/6,8,21\">",
"     6,8,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the 1995 Ebola Zaire outbreak in Kikwit, DRC, whole blood from convalescent patients was administered to eight patients late in their clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/22\">",
"     22",
"    </a>",
"    ]. Only one patient died, suggesting that even small amounts of transfused blood had a beneficial effect. However, a subsequent analysis demonstrated that, due to good prognostic factors, these patients would have likely survived without any intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/23\">",
"     23",
"    </a>",
"    ]. When transfusion of convalescent blood was duplicated in Ebola virus-infected rhesus macaques in the laboratory, no protection was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few laboratory workers accidentally infected with Marburg or Ebola Sudan virus survived their illness after receiving convalescent serum and interferon-alpha; however, since they also received other types of supportive care, these anecdotal cases do not provide evidence of therapeutic efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a recent case of laboratory exposure to Ebola Zaire virus in Russia through an accidental needle stick, treatment with interferon-alpha, immune globulin, plasma exchange, and other measures failed to rescue the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Postexposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;At this time, there are no FDA-approved forms of postexposure prophylaxis for Marburg or Ebola HF. In the event of an exposure, filovirus experts should be contacted for advice about the status of experimental therapies. In the US, such consultation can be obtained by contacting USAMRIID or the Special Pathogens Branch at CDC. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Additional resources and contact information'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A variety of substances have been tested for efficacy as postexposure prophylaxis in laboratory animals infected with Ebola Zaire virus. Interferon-alpha is highly protective in mice when therapy is started before or soon after virus challenge, but treatment of nonhuman primates with a licensed product, human interferon-alpha-2b, only slightly delayed the onset of illness and death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Treatment with interferon-beta is now being explored. Antisense molecules and siRNA have been effective in rodent models and are undergoing initial evaluation in nonhuman primates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Polyvalent or monoclonal antibodies against Ebola virus have also been protective in mice and guinea pigs, but have not altered the progression of illness in macaques [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/29,32-34\">",
"     29,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of rhesus macaques with recombinant nematode anticoagulant protein C2 (rNAPC2), beginning on the day of or the day following Ebola virus challenge, resulted in the survival of one-third of animals and significantly delayed the death of others [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/35\">",
"     35",
"    </a>",
"    ]. The same approach was somewhat less effective against the highly virulent Marburg virus isolated during the Angola outbreak [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/36\">",
"     36",
"    </a>",
"    ]. rNAPC2 inhibits triggering of the extrinsic coagulation pathway by blocking tissue factor-factor VIIa interaction, but in the surviving macaques it also suppressed systemic inflammatory responses and markedly inhibited viral replication. Recognizing the similarity between the host responses observed in filoviral hemorrhagic fever and those in septic shock, therapy with recombinant human activated protein C is also being evaluated. Continuous intravenous infusion, beginning postexposure, showed benefit in an initial experiment in Ebola-infected nonhuman primates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a very promising approach to postexposure prophylaxis, an experimental live-virus vaccine has been developed using recombinant vesicular stomatitis virus (VSV) encoding the Marburg or Ebola surface glycoproteins. A single injection is completely protective as a standard preexposure vaccine. Remarkably, it has also demonstrated protective efficacy when administered to mice or monkeys shortly after virus challenge, protecting all animals infected with Marburg or Ebola Sudan virus and half of those infected with Ebola Zaire virus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. These results indicate that the rapid induction of an antigen-specific response through the early presentation of filovirus glycoproteins to the immune system can counteract the immunosuppression induced by viral infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the CDC provides guidance on infection control measures for patients infected with a filovirus or other highly pathogenic agents. The following discussion is based on the May 2005 CDC document, \"Interim guidance for managing patients with suspected viral hemorrhagic fever in US hospitals\" (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Additional resources and contact information'",
"    </a>",
"    below). Those seeking additional information should check the CDC web site or contact the Special Pathogens Branch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some popular descriptions of bioterror outbreaks envision doctors in \"space suits\" caring for patients, this level of protection is neither needed nor recommended by public health agencies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Experience in numerous African outbreaks has shown that barrier nursing and strict observance of universal precautions in specimen handling are sufficient to prevent the transmission of filoviruses from patients to their caregivers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/16/19721?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever\", section on 'Transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even though there is no evidence that Marburg or Ebola virus is transmitted among humans by the airborne route, steps should still be taken to prevent the possibility of droplet spread from the respiratory tract as additional precautions. The patient should be placed in a private room under negative pressure, when available.",
"   </p>",
"   <p>",
"    All patient care should be performed in strict accordance with CDC directives. Access should be restricted to essential staff, who should wear gloves, gowns, face shields or surgical masks and eye protection, and employ respiratory protection (N-95 masks or powered air-purifying respirators). Additional personal protection may be needed if spilled or splashed body fluids present an additional risk. Stethoscopes and other equipment used for patient care should remain in the room. Hypodermic needles and other \"sharps\" should be used with great care and disposed of according to CDC directives. All protective gear should be removed before exiting the room, accompanied by cleaning and disinfection of shoes or other articles that cannot be discarded.",
"   </p>",
"   <p>",
"    In the event of a large-scale bioterror attack with Ebola or Marburg virus, it might become necessary to devote entire wards to patients, or even make use of spaces such as hospital storage rooms, cafeterias, or other spaces not normally employed for patient care. The use of portable forced-air systems to create negative-pressure isolation areas in a mass-casualty situation has recently been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods of decontaminating surfaces or objects contaminated with body fluids of a patient with known or suspected filovirus infection are similar to those for other blood-borne pathogens commonly encountered in hospitals. A summary document is available from the CDC web site (see below), and more detailed information can be obtained by contacting the Special Pathogens Branch. General advice regarding decontamination procedures is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The international response to Marburg and Ebola outbreaks has been aided by the development of PCR- and antigen-based field diagnostic methods, which make it possible to quickly and reliably distinguish between patients with filoviral hemorrhagic fever and those suffering from other diseases endemic to central Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although modern technology has facilitated the recognition of outbreaks and the identification of patients, the success of an outbreak intervention depends largely on effective communication with the local populace to explain the need for monitoring, sample collection and testing, isolation, and other infection control measures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. For this reason, anthropologists and other persons with specialized knowledge of local cultures are now being included as members of response teams [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1624/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES AND CONTACT INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A physician caring for a patient with suspected filoviral hemorrhagic fever should report the case to hospital infection control personnel and local public health authorities, who may in turn contact state and national agencies, including law enforcement officials, if appropriate.",
"   </p>",
"   <p>",
"    Additional advice on emergency therapy, infection control, and specimen handling can be obtained by contacting the Special Pathogens Branch, CDC Atlanta, at 404-639-1115. USAMRIID at Fort Detrick, Frederick, MD at 301-619-2833 may also be a useful source of information on experimental prophylaxis and therapy that might be employed under compassionate use protocols.",
"   </p>",
"   <p>",
"    The following documents provide current guidance on the management of filoviral infections and other cases of viral hemorrhagic fever, including infection control and decontamination procedures.",
"   </p>",
"   <p>",
"    Interim Guidance for Managing Patients with Suspected Viral Hemorrhagic Fever in US Hospitals.",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncidod/hip/BLOOD/vhf_interimGuidance.htm\">",
"     www.cdc.gov/ncidod/hip/BLOOD/vhf_interimGuidance.htm",
"    </a>",
"   </p>",
"   <p>",
"    Guideline for Isolation Precautions in Hospitals",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncidod/hip/ISOLAT/Isolat.htm\">",
"     www.cdc.gov/ncidod/hip/ISOLAT/Isolat.htm",
"    </a>",
"   </p>",
"   <p>",
"    Guideline for Environmental Infection Control in Health-Care Facilities, 2003",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov/hai/\">",
"     file://www.cdc.gov/hai/",
"    </a>",
"   </p>",
"   <p>",
"    Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncidod/dvrd/spb/mnpages/vhfmanual.htm\">",
"     www.cdc.gov/ncidod/dvrd/spb/mnpages/vhfmanual.htm",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The filoviruses, Marburg and Ebola, are among the most virulent human pathogens, causing severe hemorrhagic fever that resembles fulminant septic shock. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to their virulence, stability as aerosols, and high infectivity, Marburg and Ebola viruses are classified as Category A bioterror agents by the Centers for Disease Control and Prevention (CDC) and the National Institute of Allergy and Infectious Diseases (NIAID). The occurrence of even a single human infection outside of Africa is therefore a public health emergency requiring immediate investigation, since it could represent the leading edge of an impending outbreak. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bioterrorism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether filoviral hemorrhagic fever is initially considered in the differential diagnosis will vary markedly with the clinical and epidemiologic circumstances. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid diagnostic tests for Marburg and Ebola virus infection have been developed, based on the detection of viral antigens by enzyme-linked immunosorbent assay (ELISA) or specific RNA sequences by reverse-transcription polymerase chain reaction (RT-PCR) in blood or other body fluids. The diagnosis is confirmed through cell culture. These tests should only be performed under biocontainment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the early stages of the medical workup, when Ebola or Marburg hemorrhagic fever are only one of many possible diagnoses, specimens for laboratory testing may be labeled, transported, and tested following recommendations by the CDC for blood-borne infectious agents. Physicians desiring the performance of specific diagnostic tests by specialized laboratories must first report the suspected case to their local public health agencies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific therapy is available for patients who have developed Ebola or Marburg hemorrhagic fever; care is supportive. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patient management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although several approaches have proven beneficial in laboratory primates, no specific intervention has been approved for post-exposure prophylaxis in humans. Experts in filovirus infections should be consulted regarding possible experimental therapies. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patient management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health care workers should employ isolation and barrier nursing procedures recommended by the CDC when caring for patients with suspected or known filovirus infection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/1\">",
"      Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/2\">",
"      Bray M, Murphy FA. Filovirus research: knowledge expands to meet a growing threat. J Infect Dis 2007; 196 Suppl 2:S438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/3\">",
"      Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/4\">",
"      Rotz LD, Khan AS, Lillibridge SR, et al. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 2002; 8:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/5\">",
"      Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/6\">",
"      Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/7\">",
"      Bray M. Defense against filoviruses used as biological weapons. Antiviral Res 2003; 57:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/8\">",
"      Pigott DC. Hemorrhagic fever viruses. Crit Care Clin 2005; 21:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/9\">",
"      Martini GA. Marburg agent disease: in man. Trans R Soc Trop Med Hyg 1969; 63:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/10\">",
"      Sanchez A, Lukwiya M, Bausch D, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004; 78:10370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/11\">",
"      Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196 Suppl 2:S364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/12\">",
"      Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196 Suppl 2:S357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/13\">",
"      Li K, Thomasson D, Ketai L, et al. Potential applications of conventional and molecular imaging to biodefense research. Clin Infect Dis 2005; 40:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/14\">",
"      Ksiazek TG, West CP, Rollin PE, et al. ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 1999; 179 Suppl 1:S192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/15\">",
"      Drosten C, G&ouml;ttig S, Schilling S, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 2002; 40:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/16\">",
"      Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004; 78:4330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/17\">",
"      Towner JS, Sealy TK, Ksiazek TG, Nichol ST. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 2007; 196 Suppl 2:S205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/18\">",
"      Bray M, Pilch R. Filoviruses: recent advances and future challenges. Expert Rev Anti Infect Ther 2006; 4:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/19\">",
"      Bray M, Paragas J. Experimental therapy of filovirus infections. Antiviral Res 2002; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/20\">",
"      Jeffs B. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa. Trop Doct 2006; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/21\">",
"      Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis 2003; 188:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/22\">",
"      Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179 Suppl 1:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/23\">",
"      Sadek RF, Khan AS, Stevens G, et al. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 1999; 179 Suppl 1:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/24\">",
"      Jahrling PB, Geisbert JB, Swearengen JR, et al. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196 Suppl 2:S400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/25\">",
"      Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J 1977; 2:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/26\">",
"      Nikiforov VV, Turovski IuI, Kalinin PP, et al. [A case of a laboratory infection with Marburg fever]. Zh Mikrobiol Epidemiol Immunobiol 1994; :104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/27\">",
"      Akinfeeva, A, Aksionova, O, Vasilevich, I, et al. A case of Ebola hemorrhagic fever [Russian]. Infektsionnie Bolezni 2005; 3:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/28\">",
"      Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001; 82:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/29\">",
"      Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179 Suppl 1:S224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/30\">",
"      Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/31\">",
"      Warfield KL, Panchal RG, Aman MJ, Bavari S. Antisense treatments for biothreat agents. Curr Opin Mol Ther 2006; 8:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/32\">",
"      Parren PW, Geisbert TW, Maruyama T, et al. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76:6408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/33\">",
"      Takada A, Ebihara H, Jones S, et al. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007; 25:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/34\">",
"      Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007; 3:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/35\">",
"      Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/36\">",
"      Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007; 196 Suppl 2:S372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/37\">",
"      Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007; 196 Suppl 2:S390.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, SM, Feldmann, H, Stroher, U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/39\">",
"      Daddario-DiCaprio KM, Geisbert TW, Str&ouml;her U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/40\">",
"      Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/41\">",
"      Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82:5664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/42\">",
"      Peters CJ, Jahrling PB, Khan AS. Patients infected with high-hazard viruses: scientific basis for infection control. Arch Virol Suppl 1996; 11:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/43\">",
"      Kortepeter MG, Martin JW, Rusnak JM, et al. Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis 2008; 14:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/44\">",
"      Rosenbaum RA, Benyo JS, O'Connor RE, et al. Use of a portable forced air system to convert existing hospital space into a mass casualty isolation area. Ann Emerg Med 2004; 44:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/45\">",
"      Jeffs B, Roddy P, Weatherill D, et al. The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. I. Lessons learned in the hospital. J Infect Dis 2007; 196 Suppl 2:S154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/46\">",
"      Roddy P, Weatherill D, Jeffs B, et al. The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. II. lessons learned in the community. J Infect Dis 2007; 196 Suppl 2:S162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/47\">",
"      Boumandouki P, Formenty P, Epelboin A, et al. [Clinical management of patients and deceased during the Ebola outbreak from October to December 2003 in Republic of Congo]. Bull Soc Pathol Exot 2005; 98:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/48\">",
"      Hewlett BL, Hewlett BS. Providing care and facing death: nursing during Ebola outbreaks in central Africa. J Transcult Nurs 2005; 16:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1624/abstract/49\">",
"      Hewlett BS, Amola RP. Cultural contexts of Ebola in northern Uganda. Emerg Infect Dis 2003; 9:1242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3022 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1624=[""].join("\n");
var outline_f1_37_1624=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOTERRORISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory or health care worker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Traveler from central Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Suspected bioterrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rapid diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sample handling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATIENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PUBLIC HEALTH RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADDITIONAL RESOURCES AND CONTACT INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/16/19721?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_37_1625="Hepatitis B virus infection in renal transplant recipients";
var content_f1_37_1625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatitis B virus infection in renal transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1625/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1625/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1625/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1625/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1625/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1625/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/37/1625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hepatitis B virus (HBV) infection in dialysis patients has significantly decreased over the past few decades, probably related to aggressive immunization efforts. A national surveillance in the United States in 2002, for example, revealed that only 1.0 percent of dialysis patients were seropositive for HBsAg [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40024?source=see_link\">",
"     \"Hepatitis B virus and dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, dialysis patients with positive hepatitis B surface antigen (HBsAg) who are being considered for kidney transplantation should undergo liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/2\">",
"     2",
"    </a>",
"    ]. A kidney transplant is generally contraindicated if cirrhosis is noted [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/2\">",
"     2",
"    </a>",
"    ]. However, in the era of safe and effective antiviral therapies, patients with compensated cirrhosis may be considered for kidney transplantation. If moderate to severe hepatitis and detectable replication (positive HBeAg or HBV DNA) are found, antiviral therapy prior to transplantation may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40024?source=see_link\">",
"     \"Hepatitis B virus and dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis and management of HBV in renal transplant recipients is the subject of this review. The serologic diagnosis of HBV infection and a general overview of management are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In endemic areas, a significant number of patients who undergo kidney transplantation are HBsAg positive. The reported prevalence is approximately 15 percent of kidney transplant recipients in such locations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence is much lower in areas in which HBV is less common.",
"   </p>",
"   <p>",
"    Overall, the prevalence appears to be declining in most countries as a result of HBV vaccination programs in the general and dialysis patient population as well as the result of strict precautions to prevent transmission of HBV infection in dialysis units.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations and diagnosis of HBV infection in patients with a kidney transplantation are similar to those without renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unique issues, including the natural history and risk factors for reactivation, are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplant patients with HBV infection have inferior survival compared with patients who are not infected. A 2005 meta-analysis of six observational studies with 6050 patients reported that infection with HBV correlated with poorer outcomes post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/4\">",
"     4",
"    </a>",
"    ]. HBsAg positivity was associated with an increased risk of death (RR of 2.49, 95% CI 1.64-3.78) and allograft loss (RR of 1.44, 95% CI 1.02-2.04).",
"   </p>",
"   <p>",
"    Despite this, prolonged patient survival has been observed in some patients infected with HBV. One survey, for example, examined long-term patient survival of 42 HBsAg positive patients in a single center in Italy who received a kidney allograft between 1972 and 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/5\">",
"     5",
"    </a>",
"    ]. Patient survival at 12 years was 67 percent, which was similar to those infected with both hepatitis B and C virus (72 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/5\">",
"     5",
"    </a>",
"    ]; however, liver disease was the leading cause of death among renal transplant patients with chronic hepatitis B or C.",
"   </p>",
"   <p>",
"    The overall prognosis of HBsAg positive-patients with has improved with antiviral therapy. This was demonstrated in a retrospective study of 63 HBsAg positive patients who underwent renal transplantation between 1985 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/6\">",
"     6",
"    </a>",
"    ]. The 10-year survival rate among patients transplanted after 1996 was 81 percent. Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    had better 10- and 20- year survival rates compared with patients who were not treated (90 and 83 percent compared with 55 and 34 percent, respectively). Thus, hepatitis B should not be considered a contraindication to kidney transplantation. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Antiviral agents and approach to treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors for reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The status of the recipient, particularly serologic and virologic markers, is an important determinant of the risk of reactivation of HBV replication post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. As an example, an increased risk of death from HBV-induced liver disease post-transplant is observed in the HBsAg positive recipient who is HBV-DNA or HBeAg positive, compared with the HBsAg positive patient who is HBV-DNA or HBeAg negative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/9\">",
"     9",
"    </a>",
"    ]. A liver biopsy, performed prior to and after renal transplant, can help determine the stage of liver disease and assess the risk of liver failure post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serologic and virologic status of the donor is also a significant risk factor for de novo HBV infection post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/1\">",
"     1",
"    </a>",
"    ]. A high risk of infection is observed in the HBV negative recipient of an organ from an HBsAg-positive donor. There is a low risk of transmission of HBV infection from HBsAg-negative, anti-HBc positive donors to HBV-negative recipients; the risk is even lower if the recipient is anti-HBs positive [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fibrosing cholestatic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are rare reports of fibrosing cholestatic hepatitis, which is a histologic diagnosis first reported in patients with recurrent hepatitis B after liver transplantation. Affected patients are markedly jaundiced, have very high serum HBV DNA levels, and progress rapidly to liver failure. Liver biopsy reveals severe cholestasis and intense staining for HBV but mild to moderate necroinflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of HBV infection in renal transplant recipients is based upon consistent and effective vaccination of HBsAg-negative dialysis and chronic kidney disease patients, adequate infection control measures in dialysis units and adequate antiviral prophylaxis depending upon donor and recipient status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40024?source=see_link\">",
"     \"Hepatitis B virus and dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35959?source=see_link\">",
"     \"Immunizations in patients with end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are already on dialysis, higher doses of vaccine are recommended, with post-vaccination and subsequent annual testing and booster vaccination if anti-HBs titer falls below 10",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    In view of the relatively poor response to vaccination in renal dialysis patients, hepatitis B vaccination should be given early in the course of chronic kidney disease. Post-vaccination testing is recommended to confirm that the patient has had an adequate response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT PRIOR TO TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All HBV patients should be tested for HBeAg and serum HBV DNA prior to kidney transplant. Issues surrounding the evaluation and management of dialysis patients prior to transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40024?source=see_link\">",
"     \"Hepatitis B virus and dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POST-TRANSPLANT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, reactivation of HBV replication (increase in serum HBV DNA or appearance of serum HBV DNA in a patient with previously undetectable HBV DNA) may occur after kidney transplantation secondary to the use of immunosuppressive therapy. Reactivation of HBV replication is more likely to occur in patients who were HBeAg positive or had detectable serum HBV DNA prior to transplant; however, reactivation can also occur in patients who were HBeAg negative or had undetectable serum HBV DNA prior to transplant. Reactivation of HBV replication has also been reported in those who were HBsAg-negative and anti-HBc positive.",
"   </p>",
"   <p>",
"    With reactivation, an increase in serum HBV DNA levels usually precedes an increase in ALT levels. In some patients, reactivation may result in hepatitis flares and, rarely, hepatic failure and death. In general, both allograft and patient survival is decreased.",
"   </p>",
"   <p>",
"    Although a paucity of data exists in kidney transplant patients, a large body of evidence in the non-transplant setting indicates that treatment with antiviral therapy after hepatic dysfunction or aminotransferase elevation is detected is less effective in preventing hepatic flares or hepatic decompensation than that associated with a preventive approach. Thus, based largely upon evidence in the non-transplant setting as well as some data in kidney transplant patients, we recommend preventive therapy in patients with HBV infection undergoing kidney transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Overview of preventive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two principal approaches to prevention of post-transplant HBV reactivation in kidney allograft recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prophylactic strategy involves the administration of antiviral agents to patients at increased risk of developing HBV reactivation either prior to or immediately after transplantation. This strategy prevents reactivation of hepatitis in patients receiving cancer chemotherapy and bone marrow transplantation. It is unclear whether antiviral prophylaxis should be recommended for all HBV infected patients, only those who are HBeAg positive, or only those with detectable serum HBV DNA prior to kidney transplant.",
"      <br/>",
"      <br/>",
"      If administered, there is no consensus regarding the duration of antiviral prophylaxis. Nevertheless, most experts would recommend preventive antiviral therapy for all HBsAg positive patients during at least the first one to two years, when immunosuppressive therapy is most intense. Whether antiviral therapy can be discontinued in patients who were HBeAg negative or had undetectable serum HBV DNA prior to transplant and are currently maintained on minimal immunosuppression has not been determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A preemptive strategy involves periodic monitoring for viremia after transplantation. This principally involves using the polymerase chain reaction (PCR) assay to permit prompt treatment after the detection of HBV DNA in a patient who previously had undetectable serum HBV DNA or a marked increase (eg, 10-fold or 1 log) in serum HBV DNA in a patient who previously had a low serum HBV DNA level. Thus, this approach requires close monitoring of serum HBV DNA and may not always be feasible in clinical practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Efficacy studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of evidence exists concerning the relative efficacy of preventive strategies. There are no studies in the kidney transplant setting that have directly compared outcomes with a prophylactic versus a preemptive approach.",
"   </p>",
"   <p>",
"    However, either strategy provides superior outcomes, including patient survival, versus that observed with antiviral therapy administered only after clinically significant reactivation of hepatitis B virus. We therefore recommend preventive therapy in kidney transplant recipients infected with the hepatitis B virus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preemptive approach",
"      </strong>",
"      &mdash; A preemptive strategy appears to improve overall survival of kidney transplant recipients. One study, for example, compared the outcomes of patients treated preemptively with the antiviral agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      using strict criteria (group 2, de novo transplantation) versus an older historic control group who may or may not have been treated preemptively with lamivudine (group 1, historical group), with variable criteria for treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Group 2 consisted of 12 patients treated if one of the following occurred: HBV DNA level greater than 1000",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (&gt;8 log10",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      in those with normal ALT levels; or HBV DNA level greater than 100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (&gt;7 log10",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      in those with increased ALT levels",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a significant hepatitis on liver biopsy. Eleven patients in group 2 eventually required lamivudine at an average period of 8.4 months after transplantation.",
"      <br/>",
"      <br/>",
"      There were 38 surviving patients in group 1, of whom 15 were treated preemptively with lamivudine at a mean period of 71 months after transplantation. Treatment was initiated in seven and eight patients based upon HBV DNA levels alone or abnormal ALT levels plus HBV DNA levels, respectively.",
"      <br/>",
"      <br/>",
"      Survival of group 2 patients was similar to HBsAg-negative controls, which (as previously noted) is associated with the lowest mortality. By comparison, survival of all group 1 patients (some of whom died prior to the institution of preemptive therapy) was markedly inferior to HBsAg-negative controls (relative risk of death of 9.7, 95% CI 4.7-19.9). In addition, discontinuation of lamivudine was successful in 5 of 12 patients at low risk for reactivation.",
"     </li>",
"     <li>",
"      <strong>",
"       Prophylactic approach",
"      </strong>",
"      &mdash; The best evidence that a prophylactic strategy with antiviral therapy may be effective in preventing reactivation of hepatitis B virus is provided by small clinical studies in the non-kidney transplant setting, in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      has been given to those undergoing chemotherapy for malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There is also some evidence that this strategy may provide benefits in kidney transplant recipients, although studies have largely consisted of open label uncontrolled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/12,15,16\">",
"       12,15,16",
"      </a>",
"      ]. In one retrospective study of 17 HBsAg-positive patients, liver biopsy revealed minimal inflammation in 14 patients and active hepatitis in three [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/15\">",
"       15",
"      </a>",
"      ]. Lamivudine was administered pre-operatively in the three individuals with hepatitis and an additional seven for post-operative liver dysfunction. Treatment was administered for 36 months. HBV DNA became initially negative in 9 of 10 patients, but four patients had redetection of HBV DNA, possibly due to drug resistance. All 17 patients had functioning grafts, except for one patient who developed relapsed IgA nephropathy.",
"      <br/>",
"      <br/>",
"      One uncontrolled prospective study suggests that patient survival is improved with preemptive lamivudine therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/12\">",
"       12",
"      </a>",
"      ]. Outcomes were compared in patients who underwent renal transplant before and after the program-wide implementation of a preventive strategy in which lamivudine was administered to patients based upon increasing HBV levels (with or without elevated aminotransferase levels). Whereas among 15 HBsAg-positive patients transplanted prior to implementation of this strategy, survival rates were inferior to HBsAg-negative patients (RR 9.7), survival of 11 patients who were transplanted after implementation of pre-emptive lamivudine was comparable to HBsAg-negative patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies have also found that treatment after hepatic dysfunction or aminotransferase elevation is detected is less effective in terms of preventing hepatic flares or hepatic decompensation than either a prophylactic or preemptive strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/3,17\">",
"     3,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data evaluating antiviral therapies other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    therapy for preventive therapy in HBV infected kidney transplantation. As delineated below, additional possible agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Based upon relative efficacy and low incidence of resistance, we suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    as the antiviral agent of choice for either prophylactic or preemptive therapy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Antiviral agents and approach to treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Our approach for prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, there are no studies in the kidney transplant setting that directly compare a preemptive versus a prophylactic approach. Although unproven, one could postulate that better outcomes would be observed with effective antiviral therapy administered just prior to or immediately after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is our approach to the prevention of HBV reactivation in kidney transplant recipients infected with HBV:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with detectable HBV DNA prior to kidney transplantation, we suggest the administration of prophylactic antiviral therapy prior to or at the time of surgery. Our rationale is that such patients are at markedly increased risk of reactivation, resulting in significant morbidity and mortality if untreated. In addition, this strategy has been shown to prevent reactivation of hepatitis in patients receiving cancer chemotherapy and bone marrow transplantation. Our preferred antiviral agent is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      , which is dosed for degree of renal insufficiency.",
"     </li>",
"     <li>",
"      Among those infected with HBV but without detectable HBV DNA just prior to transplantation, we suggest a preemptive approach. This approach places an emphasis on minimizing drug exposure and the risk of drug resistance. We monitor serum HBV DNA every three months for the first year and every six months thereafter. Antiviral therapy is initiated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      when serum HBV DNA becomes persistently detectable or increases progressively. Once treatment is started, we monitor HBV DNA levels every three months, or minimally every six months. If frequent monitoring of serum HBV DNA levels is not feasible, we recommend a prophylactic approach, at least for the first one to two years post-transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subset of patients who are anti-HBc positive and HBs antigen negative are at lower risk of reactivation post-transplantation. Thus, most clinicians check HBV DNA levels only if ALT levels are increased. However, some clinicians would monitor HBV DNA levels regardless of ALT and use a preemptive approach based upon HBV DNA levels alone.",
"   </p>",
"   <p>",
"    Among immunocompetent patients, laboratory and clinical features such as HBeAg seroconversion permit the successful discontinuation of antiviral therapy. However, there are currently no data that this approach can be applied to kidney transplant patients. As a result, kidney transplant recipients require life-long immunosuppressive therapy. Nevertheless, among patients with undetectable HBV DNA prior to transplant, it may be possible to discontinue antiviral therapy when immunosuppressive therapy is decreased to a single drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANTIVIRAL AGENTS AND APPROACH TO TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-transplantation, all patients should be closely monitored for viral relapse, hepatitis flares, and hepatic dysfunction. Issues related to the treatment of hepatitis B virus infection in kidney transplant recipients include the specific manifestations of the disease, whether antiviral therapy is currently being administered, and the choice of antiviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Antiviral naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who underwent kidney transplant prior to the availability of oral antiviral therapies for preventive therapy, the decision regarding when antiviral therapy should be initiated is based upon the degree of elevation of aminotransferases, liver histology, HBV serology, and HBV DNA levels. Kidney transplant patients tend to have higher HBV DNA levels due to immunosuppression while ALT may be lower, compared to those in the nontransplant setting. Thus, serum HBV DNA and liver histology may be better indicators for treatment than the ALT level. We therefore biopsy all patients prior to initiation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional factors underlying management include the duration of therapy, definitions of treatment response, desired clinical outcomes, and patient monitoring. These issues are discussed in detail separately and are not reviewed in this section. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Patients receiving antiviral preventive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that all infected kidney transplant recipients receive either prophylactic or preemptive therapy (if possible), the treatment of significant hepatic disease in the patient already receiving antiviral therapy will vary in part based on the agent currently being administered and the manifestations of the disease. This as well as other issues concerning management are discussed in detail below and separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Antiviral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal antiviral agent(s) for the treatment of renal transplant recipients with chronic hepatitis B infection is unclear. In the non-renal transplant population, options include interferon and five currently approved oral antiviral therapies:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . Entecavir, telbivudine, and tenofovir are the most potent, followed by lamivudine and then adefovir. Entecavir and tenofovir are associated with the lowest risk of drug resistance, followed by adefovir, then telbivudine and lamivudine.",
"   </p>",
"   <p>",
"    There are very limited data on the use of these agents in kidney transplant patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    has been most extensively used in this setting, but it is associated with a high rate of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    has been less frequently used, due in part to potential nephrotoxicity with this agent.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is also associated with a small risk of nephrotoxicity.",
"   </p>",
"   <p>",
"    There are few studies concerning the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    in kidney transplant recipients. In the non-transplant patient, entecavir has been associated with the lowest rate of drug resistance and therefore may be the preferred treatment, since long-term therapy will be needed in most renal transplant patients.",
"   </p>",
"   <p>",
"    All five oral antiviral agents are renally excreted and, if used, dose adjustments must be made in patients with decreased estimated glomerular filtration rates. (See appropriate drug information reviews).",
"   </p>",
"   <p>",
"    Although there are no studies in the transplant setting, we suggest initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    because of its relative potency, low rate of resistance with long-term treatment, and lack of nephrotoxicity compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . Tenofovir may be an acceptable alternative, but it has been associated with nephrotoxicity. In those who have already begun treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and have developed resistance, adefovir or tenofovir (preferred to adefovir in countries where this is available) can be added to lamivudine (rather than stopping lamivudine), since combination therapy may reduce the development of resistance to the second drug.",
"   </p>",
"   <p>",
"    Since interferon alfa may precipitate acute allograft rejection, interferon alfa should NOT be used in kidney transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287959240\">",
"    <span class=\"h4\">",
"     Lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is effective in kidney transplant recipients infected with hepatitis B virus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. To best assess the efficacy of lamivudine, a 2004 meta-analysis of 14 clinical trials consisting of 184 patients was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/25\">",
"     25",
"    </a>",
"    ]. Clearance of HBV-DNA and HBeAg was observed in 91 and 27 percent, respectively; normalization of alanine aminotransferase occurred in 81 percent, with lamivudine resistance being reported in 18 percent. Frequency of loss of HBeAg and lamivudine resistance correlated with duration of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent studies have found that prolonged",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    monotherapy (24 to 69 months) normalized alanine aminotransferase in 33 to 77 percent of patients and cleared HBeAg and HBV-DNA in zero to 25 percent and 43 to 78 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is an increasing incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance with longer duration of lamivudine treatment. In one review of several prospective studies published between 2002 to 2005, the cumulative probability of developing lamivudine resistance was approximately 60 percent after therapy for 24 to 69 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/6,19,26-30\">",
"     6,19,26-30",
"    </a>",
"    ]. As an example, one report of 29 renal transplant patients who received almost 60 months of therapy noted that 14 (48 percent) developed lamivudine resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/26\">",
"     26",
"    </a>",
"    ]. Among the patients with lamivudine resistance, hepatic flares were observed in 11 (79 percent), which were transient in four but persistent in six. All patients with lamivudine resistance survived, but hepatic decompensation during a flare was observed in one individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link&amp;anchor=H11#H11\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\", section on 'Resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is associated with the highest rate of drug resistance among the available oral antiviral agents. This is followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , and then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287959247\">",
"    <span class=\"h4\">",
"     Adefovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    in kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In one prospective observational study of 12 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant hepatitis B virus infection, adefovir was administered to 11 post-kidney transplant patients, of whom one had re-initiated hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/31\">",
"     31",
"    </a>",
"    ]. The dose was adjusted based on renal function. At one year, there was a decline in serum HBV DNA (8.76 to 2.97 log10",
"    <span class=\"nowrap\">",
"     Eq/mL),",
"    </span>",
"    with no virologic breakthroughs. Renal function as determined by the creatinine clearance actually improved with therapy.",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    is associated with nephrotoxicity including renal insufficiency and renal tubular abnormalities. As a result, it must be used with caution in patients with impaired renal function. In addition, the antiviral activity of adefovir at the currently approved doses is weak and efficacy may be reduced in patients who require dose adjustment due to renal insufficiency. Dosing and Renal impairment is discussed separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     \"Adefovir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    has similar activity against wild-type and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV. The development of resistance to adefovir may also occur. Clinical trials in chronic hepatitis B patients have reported rates of resistance of approximately 30 percent after five years of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287959254\">",
"    <span class=\"h4\">",
"     Entecavir, telbivudine, and tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the non-renal transplant population,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are the most potent antiviral agents, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . There are no published data concerning the efficacy of telbivudine and tenofovir in kidney transplant recipients. There is one study of 10 transplant patients (eight kidney recipients) resistant to adefovir or lamivudine who were administered entecavir [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/33\">",
"     33",
"    </a>",
"    ]. At follow-up of approximately 17 months, there was a significant decrease in HBV DNA viral load, and the rate of HBV clearance was 50 percent in HBeAg+ and HBeAg- patients.",
"   </p>",
"   <p>",
"    The efficacy of these agents must be considered in the context of viral resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , the agent used most frequently in this setting. Patients with lamivudine-resistant HBV will not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    as both drugs select for the same mutations. These patients will respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , but lamivudine-resistant HBV is less sensitive to entecavir as wild-type HBV (without lamivudine-resistant mutations). Despite the use of a higher dose of entecavir, the rate of entecavir resistance is higher in patients with prior lamivudine resistance compared with patients who have not been exposed to lamivudine. The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is preferred in patients with lamivudine-resistant HBV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    appears to be the best treatment in nucleoside-na&iuml;ve patients because of the low rate of drug resistance, approximately 1 percent after five years of therapy. However, there are no data concerning its use in kidney transplant patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H287959261\">",
"    <span class=\"h4\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa has low efficacy in immunosuppressed patients and may precipitate acute allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. As a result, interferon alfa should NOT be used in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1625/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reported prevalence of patients undergoing kidney transplantation who are HBsAg positive varies widely. In endemic areas, the prevalence may be 15 percent, while it is much lower in non-endemic areas. This prevalence is on the decline. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kidney transplant patients with hepatitis B virus (HBV) infection have inferior survival compared with patients who are not infected; however, most of these data were generated prior to the availability of effective antiviral therapies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The status of the recipient, particularly serologic and virologic markers, is an important determinant of the risk of reactivation of HBV replication post-transplant. In addition, the serologic and virologic status of the donor is also a significant risk factor for de novo HBV infection post-transplant. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors for reactivation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of HBV infection among renal transplant recipients is based upon consistent and effective vaccination of HBsAg-negative dialysis and chronic kidney disease patients, adequate infection control measures in dialysis units, as well as antiviral prophylaxis post-transplant. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40024?source=see_link\">",
"       \"Hepatitis B virus and dialysis patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35959?source=see_link\">",
"       \"Immunizations in patients with end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The two principal approaches to prevention of post-transplant HBV reactivation in kidney allograft recipients are a prophylactic or a preemptive strategy. A prophylactic strategy involves the administration of antiviral agents to patients at increased risk of developing HBV reactivation either prior to or immediately after transplantation. A preemptive strategy involves periodic monitoring for viremia after transplantation, with prompt treatment after the detection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increase in HBV DNA levels. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Overview of preventive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following recommendations are based upon the few studies in kidney transplant recipients in combination with the large number of studies in the general population infected with hepatitis B virus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients infected with hepatitis B virus who undergo kidney transplantation, we recommend the use of a preventive approach to limit the risk of HBV reactivation post-transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Overview of preventive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic or preemptive strategies are the two principal approaches to prevention of post-transplant HBV reactivation in kidney allograft recipients. There are no studies that have directly compared these two approaches. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Efficacy studies'",
"      </a>",
"      above.) We use the following approach based upon the presence or absence of plasma HBV DNA prior to transplantation:",
"      <br/>",
"      <br/>",
"      - Among those with detectable plasma HBV DNA prior to transplantation, we suggest the use of a prophylactic strategy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      - Among those infected with HBV but without detectable plasma HBV DNA prior transplantation, we suggest the use of a preemptive strategy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some prefer the use of a prophylactic strategy in this setting.",
"      <br/>",
"      <br/>",
"      With either strategy, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      as the antiviral agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Given that kidney transplant recipients are immunocompromised, we suggest the administration of antiviral therapy indefinitely, particularly for patients who had detectable HBV DNA prior to transplant (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Our approach for prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Antiviral agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-transplantation, all patients should be closely monitored for viral relapse, hepatitis flares, and hepatic dysfunction. Issues related to the treatment of hepatitis B virus infection in kidney transplant recipients include the specific manifestations of the disease, whether antiviral therapy is currently being administered, and the specific choice of antiviral therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are five currently available oral antiviral agents:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      . Entecavir, telbivudine, and tenofovir are the most potent, followed by lamivudine and then adefovir. In addition, lamivudine is associated with the highest rate of drug resistance, followed by telbivudine, adefovir, and then tenofovir and entecavir. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Antiviral agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among those in whom antiviral therapy is required, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      because of its relative potency, low rate of resistance with long-term treatment, and lack of nephrotoxicity compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Tenofovir is an acceptable alternative but it has been associated with nephrotoxicity. Since interferon alfa may precipitate acute allograft rejection, we recommend NOT administering interferon alfa in kidney transplant recipients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Antiviral agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among those who have already begun treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      and have developed resistance,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      can be added to lamivudine (rather than stopping lamivudine), since combination therapy may reduce the development of resistance to the second drug.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/1\">",
"      Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     Magee, CC. Evaluation of donors and recipients. In: Chronic Kidney Disease, Dialysis, and Transplantation, 2nd Edition, Pereira, BJ, Sayegh, MH, Blake, B (Eds). Elsevier Saunders 2005, Philadelphia, United States.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/3\">",
"      Han DJ, Kim TH, Park SK, et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001; 71:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/4\">",
"      Fabrizi F, Martin P, Dixit V, et al. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/5\">",
"      Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/6\">",
"      Yap DY, Tang CS, Yung S, et al. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/7\">",
"      Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005; 16:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/8\">",
"      Duhart BT Jr, Honaker MR, Shokouh-Amiri MH, et al. Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. Transpl Infect Dis 2003; 5:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/9\">",
"      Fairley CK, Mijch A, Gust ID, et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 1991; 52:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/10\">",
"      Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/11\">",
"      Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/12\">",
"      Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/13\">",
"      Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/14\">",
"      Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/15\">",
"      Park SK, Yang WS, Lee YS, et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001; 16:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/16\">",
"      Lewandowska D, Durlik M, Kukua K, et al. Treatment of chronic hepatitis B with lamivudine in renal allograft recipients. Transplant Proc 2000; 32:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/17\">",
"      Filik L, Karakayali H, Moray G, et al. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen. Transplant Proc 2006; 38:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/18\">",
"      Perrillo RP. Hepatitis B and renal transplantation: securing the sword of damocles. Hepatology 2002; 36:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/19\">",
"      Fabrizi, F, Martin, P. Management of hepatitis B and C virus infection before and after renal transplantation. Curr Opin Organ Transplant 2006; 11:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/20\">",
"      Rostaing L, Henry S, Cisterne JM, et al. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/21\">",
"      Chan TM, Wu PC, Li FK, et al. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/22\">",
"      Kletzmayr J, Watschinger B, M&uuml;ller C, et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/23\">",
"      Lee WC, Wu MJ, Cheng CH, et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/24\">",
"      Lau SC, Tse KC, Lai WM, Chiu MC. Use of prophylactic lamivudine and mycophenolate mofetil in renal transplant recipients with chronic hepatitis B infection. Pediatr Transplant 2003; 7:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/25\">",
"      Fabrizi F, Dulai G, Dixit V, et al. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/26\">",
"      Chan TM, Tse KC, Tang CS, et al. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004; 4:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/27\">",
"      Kamar N, Sandres-Saune K, Ribes D, et al. Effects of long-term lamivudine therapy in renal-transplant patients. J Clin Virol 2004; 31:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/28\">",
"      Thabut D, Thibault V, Bernard-Chabert B, et al. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2004; 16:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/29\">",
"      Vigan&ograve; M, Colombo M, Aroldi A, et al. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis. Antivir Ther 2005; 10:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/30\">",
"      de Silva HJ, Herath CA, Sheriff MH. Lamivudine therapy for hepatitis B infection in post-renal transplant patients: results after 36 months follow-up. Liver Int 2005; 25:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/31\">",
"      Fontaine H, Vallet-Pichard A, Chaix ML, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/32\">",
"      Kamar N, Huart A, Tack I, et al. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol 2009; 71:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/33\">",
"      Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/34\">",
"      Rostaing L, Modesto A, Baron E, et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/35\">",
"      Durlik M, Gaciong Z, Rowiska D, et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11 Suppl 1:S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1625/abstract/36\">",
"      Fehr T, Amb&uuml;hl PM. Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19:1049.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7354 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FE8AB3007C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1625=[""].join("\n");
var outline_f1_37_1625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors for reactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fibrosing cholestatic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION AND MANAGEMENT PRIOR TO TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POST-TRANSPLANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Overview of preventive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Efficacy studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Our approach for prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANTIVIRAL AGENTS AND APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Antiviral naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Patients receiving antiviral preventive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Antiviral agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H287959240\">",
"      Lamivudine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H287959247\">",
"      Adefovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H287959254\">",
"      Entecavir, telbivudine, and tenofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H287959261\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=related_link\">",
"      Adefovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40024?source=related_link\">",
"      Hepatitis B virus and dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35959?source=related_link\">",
"      Immunizations in patients with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=related_link\">",
"      Telbivudine in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_37_1626="Reduced sensitivity to thyroid hormone";
var content_f1_37_1626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reduced sensitivity to thyroid hormone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1626/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1626/contributors\">",
"     Samuel Refetoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1626/contributors\">",
"     Alexandra M Dumitrescu, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1626/contributors\">",
"     Roy E Weiss, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1626/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1626/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1626/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/37/1626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/37/1626/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/37/1626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to thyroid hormone (RTH), a syndrome of reduced end-organ responsiveness to thyroid hormone (TH), was identified in 1967 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/1\">",
"     1",
"    </a>",
"    ]. With the recognition of TH receptor (TR) beta gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], the term RTH became synonymous with defects of the TR [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/4\">",
"     4",
"    </a>",
"    ]. Recent discoveries of genetic defects that reduce the effectiveness of TH through altered cell membrane transport [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/7\">",
"     7",
"    </a>",
"    ] broadened the definition of reduced TH sensitivity to include all defects that interfere with the biological activity of an authentic hormone secreted in normal amounts.",
"   </p>",
"   <p>",
"    In this topic review, the term \"reduced sensitivity to TH\" (RSTH) is used to describe any process that impairs the effectiveness of thyroid hormone, while the term \"resistance to thyroid hormone\" (RTH) is limited to the syndrome produced by reduced intracellular action of T3, the active TH. RTH can be caused by several different mechanisms, including mutations of the TH receptor beta gene, as outlined below:",
"   </p>",
"   <p>",
"    Reduced sensitivity to TH (RSTH)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resistance to thyroid hormone (RTH)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TH receptor defects",
"     </li>",
"     <li>",
"      RTH of unknown etiology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid hormone cell transporter defect (THCTD)",
"     </li>",
"     <li>",
"      Thyroid hormone metabolism defect (THMD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disorders that cause reduced sensitivity to thyroid hormone will be discussed here. Resistance to thyrotropin and thyrotropin-releasing hormone will be discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link\">",
"     \"Resistance to thyrotropin and thyrotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL THYROID HORMONE PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of thyroid hormone (TH) supply is insured by a feedback control mechanism involving the hypothalamus, pituitary, and thyroid gland, as shown in panel A (",
"    <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"     figure 1",
"    </a>",
"    ). A decreased TH supply stimulates secretion of thyrotropin releasing hormone (TRH) from the hypothalamus and thyroid stimulating hormone (TSH) from the anterior pituitary thyrotrophs, which in turn stimulates thyroid follicular cells to synthesize and secrete TH. Conversely, TH excess shuts down the system through the same pathway until a steady state is restored.",
"   </p>",
"   <p>",
"    Local requirements for TH are adjusted through additional mechanisms. One such system is the control of TH entry into the cell through active transmembrane transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/8\">",
"     8",
"    </a>",
"    ]. Another is the activation of the prohormone T4 (thyroxine) by removal of one of the outer ring iodine atoms (5'-deiodination) to form T3, or the inactivation of T4 and T3 by inner ring (5-deiodination) to form reverse T3 (rT3) and T2, respectively, as shown in panel B (",
"    <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"     figure 1",
"    </a>",
"    ). Changing concentrations of deiodinases in various cell types allows an additional local regulation of hormone supply [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the presence and abundance of TH receptors (TR), through which TH action is mediated, determine the type and degree of hormonal response. Action takes place in the cytosol as well as in the nucleus of the target cell [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/10\">",
"     10",
"    </a>",
"    ]. The latter, known as a genomic effect, has been more extensively studied, as shown in panel C (",
"    <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In the nucleus, TRs act as transcription factors that regulate expression of specific genes, which are recognized through a DNA sequence known as the TH response element. Through this mechanism, genes such as that for type 1 iodothyronine deiodinase are upregulated, and the gene for thyrotropin beta subunit is downregulated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different mechanisms that cause reduced sensitivity to thyroid hormone (RSTH) have been described, and others are postulated, as outlined below. Although the clinician considers these defects when confronted with thyroid function tests that show a discordance of serum TH and TSH concentrations, each defect has its own constellation of test abnormalities and different clinical presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Thyroid hormone cell transport defect (THCTD)",
"      </strong>",
"      &ndash; Reduced intracellular levels of TH can be caused by defects in one of the transport proteins that allow TH to enter cells (",
"      <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"       figure 1",
"      </a>",
"      ). Defective cell-transport proteins may not reach the cell membrane, or may not be able to transport the hormone. The resulting disorder depends on the specific hormone transporter affected. As an example, a defect in the monocarboxylate transporter 8 (MCT8) causes elevated serum concentrations of T3 and low levels of T4 and rT3; this defect also causes a severe psychomotor deficit [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/5\">",
"       5",
"      </a>",
"      ]. This transporter is involved in the secretion of TH from the thyroid gland [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Thyroid hormone metabolism defect (THMD)",
"      </strong>",
"      &ndash; T4, the major product secreted by the thyroid gland, is a prohormone that must be activated by conversion to T3 in the cell cytoplasm, as shown in panel B (",
"      <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"       figure 1",
"      </a>",
"      ). Defects in any of the factors involved in this enzymatic deiodination reaction can cause a diminished production of T3, and thus reduced sensitivity to TH. Defects may include abnormalities in the synthesis or degradation of the various deiodinases. As an example, some individuals have defective synthesis of selenoproteins, a family of proteins to which deiodinases belong [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients present low serum T3 and high T4 and rT3 concentrations.",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal hormone transfer to the nucleus",
"      </strong>",
"      &ndash; Before it can exert its genomic effects, TH must be transported into the nucleus where it interacts with the TH receptor (TR) to regulate transcription of target genes, as shown in panel C (",
"      <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"       figure 1",
"      </a>",
"      ). Putative defects in transfer of hormone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      its receptor to the nucleus are expected to reduce the hormonal action at the genomic level. However, no patients have been described to date whose TH resistance is caused by this mechanism. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Thyroid hormone receptor defect",
"      </strong>",
"      &ndash; The genomic action of TH within the nucleus is mediated through the TRs. TRs are transcription factors that activate or repress transcription of specific target genes, as shown in panel C (",
"      <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"       figure 1",
"      </a>",
"      ). Mutant TR proteins have reduced ability to bind cognate ligand or protein co-factors or to bind to DNA. Patients with TR gene mutations have persistent elevations of all three serum iodothyronines with non-suppressed TSH.",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal cofactors or interfering substances",
"      </strong>",
"      &ndash; Nuclear hormone receptors including TR act in concert with a complex of accessory and modulatory proteins as well as the ligand, as shown in panel C (",
"      <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"       figure 1",
"      </a>",
"      ). Putative defects in cofactors that normally stabilize the hormone-receptor complex or cofactors that repress or activate function could be responsible for reduced hormone sensitivity. As an example, some individuals have a phenotype that mimics that of a TR beta gene mutation, but have no identifiable TR gene mutation; this phenotype is thought to be caused by defects in TR cofactors. Although no such defect has been definitively identified.",
"     </li>",
"     <li>",
"      <strong>",
"       Postreceptor and non-genomic abnormalities",
"      </strong>",
"      &ndash; TH also can act at the level of the cytosol through non-genomic mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/10\">",
"       10",
"      </a>",
"      ]. The clinical effects of defects in this component of TH action have not been defined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RESISTANCE TO THYROID HORMONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to thyroid hormone (RTH) is an inherited syndrome characterized by reduced responsiveness of target tissues to thyroid hormone (TH). The disorder is characterized by high serum concentrations of free T4 and usually free T3, accompanied by normal or slightly high serum TSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. The diagnosis of RTH is confirmed if supra-physiologic doses of T4 or T3 are required to reduce the TSH secretion or induce the appropriate responses in peripheral tissues, such as an increase in serum sex-hormone binding globulin and reduction in cholesterol concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thyroid hormone action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expression of TH effects requires the presence in the cell of sufficient amounts of the active hormone, T3. The best-studied effect involves the translocation of T3 into the nucleus where it interacts with TRs to regulate (activate or repress) transcription of target genes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/12\">",
"     12",
"    </a>",
"    ]. There are two TRs, alpha and beta, which are encoded by separate genes located on chromosomes 17 and 3, respectively. The receptors have structural and sequence similarities and exist as different isoforms with DNA-binding and the T3-binding domains (",
"    <a class=\"graphic graphic_figure graphicRef77294 \" href=\"UTD.htm?6/2/6180\">",
"     figure 2",
"    </a>",
"    ). Other regions of the molecules are involved in dimerization with another TH receptor (homodimerization) or another type of nuclear receptor (heterodimerization), and in binding corepressor and coactivator protein cofactors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dimers of unliganded (without T3) receptors bind to TH-response elements (TRE) and recruit corepressor proteins, resulting in inhibition of the expression of genes that are positively regulated by T3. When T3 binds to the receptors the TR molecule undergoes a steric change that results in release of the corepressor protein, dissociation of the dimers, and formation of heterodimers of TR and retinoid X receptors that then bind coactivator proteins (",
"    <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"     figure 1",
"    </a>",
"    ). These changes promote expression of the target genes and ultimately increase the synthesis of specific proteins (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10200?source=see_link\">",
"     \"Thyroid hormone action\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, RTH was subdivided into generalized (GRTH), isolated pituitary (PRTH), and isolated peripheral tissues resistance (PTRTH). This classification was based upon clinical findings alone, and has no consistent genetic basis. Indeed, pituitary and generalized resistance to TH can occur in individuals with the same mutation. Isolated peripheral tissue resistance to TH could be the consequence of the development of tolerance to the ingestion of excess TH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prevalence and inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;RTH has been detected in 1 of 40,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/16\">",
"     16",
"    </a>",
"    ], and it occurs with equal frequency in both sexes. With the exception of a single family, it is inherited as an autosomal dominant trait.",
"   </p>",
"   <p>",
"    More than 1000 individuals belonging to 372 families have been shown to have RTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/17\">",
"     17",
"    </a>",
"    ]. Of these, 183 families were investigated in the author's institution. TR beta gene mutations were identified in 85 percent and of those, 28 percent occurred de-novo (",
"    <a class=\"graphic graphic_figure graphicRef77294 \" href=\"UTD.htm?6/2/6180\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All tissues in patients with RTH that express TR beta are resistant to action of T3, although the severity of the resistance varies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thyroid hormone receptor mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 85 percent of cases, RTH is due to mutations in the TR beta gene. One hundred and twenty-four different mutations have been identified so far among 343 unrelated families. Most of the mutations are located in the T3-binding domain of the TR (",
"    <a class=\"graphic graphic_figure graphicRef77294 \" href=\"UTD.htm?6/2/6180\">",
"     figure 2",
"    </a>",
"    ). They interfere with the function of the normal TR (dominant negative effect).",
"   </p>",
"   <p>",
"    One family has been described in which the affected subjects had complete deletion of the TR beta gene [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/18\">",
"     18",
"    </a>",
"    ]. This was inherited in a recessive manner because the single normal allele in heterozygotes was sufficient for normal function. Somatic mutations in the TR beta gene have been identified in two TSH-producing pituitary adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of hormonal resistance varies among different tissues in an affected individual, and also varies among different subjects carrying the same gene mutation. The reasons for this variability are poorly understood, but studies of transgenic mice bearing TR beta gene mutations and gene deletions have provided some insight [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/20\">",
"     20",
"    </a>",
"    ]. As an example, the tachycardia that occurs in patients with RTH is probably caused by the high serum T4 and T3 concentrations in the heart, an organ expressing predominantly the TR alpha isoform [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The variable manifestations of RTH among affected sibs with the same mutation are unexplained, but they probably result from genetic variability of cofactors involved in TH action [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three cases of a dominant negative mutation in the TR alpha gene have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The patients presented with clinical features typical of hypothyroidism, and particularly delayed skeletal development, but had low thyroxine levels and normal or high triiodothyronine levels. The hypothalamic-pituitary axis responded to exogenous thyroid hormone, but the skeletal, gastrointestinal, and myocardial tissues were resistant in at least one of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/24\">",
"     24",
"    </a>",
"    ]. This differential sensitivity to thyroid hormone action is consistent with the differential tissue expression of the TR alpha subtype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     NonTR-RTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 15 percent of families, RTH is not caused by a TR beta gene mutation; this is known as \"nonTR-RTH\". It is clinically and biochemically indistinguishable from RTH with TR beta gene mutations (",
"    <a class=\"graphic graphic_figure graphicRef75538 \" href=\"UTD.htm?34/48/35587\">",
"     figure 3",
"    </a>",
"    ). Mosaicism should be excluded by sequencing the receptor in DNA obtained from different tissues. However, mosaicism has been ruled out in several of these families in which inheritance was autosomal dominant and mutations in both TR beta and TR alpha genes have been excluded by the absence of genetic cosegregation. Mutations of one of the cofactors that interact with the receptors may be responsible for the resistance in these families [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24641580\">",
"    <span class=\"h3\">",
"     Associated abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;RTH is associated with an increased risk for autoimmune thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus the presence of antibodies to thyroperoxidase and thyroglobulin should not detract from the investigation of RTH if thyroid function tests suggest this possibility. By contrast, the occasional co-occurrence of RTH with somatic abnormalities and other congenital thyroid defects such as Pendred&rsquo;s syndrome and lingual thyroid appears to be coincidental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Effects on the hypothalamic-pituitary-thyroid axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In RTH, resistance of the pituitary thyrotrophs to TH raises TSH secretion, which increases the synthesis and secretion of T4 and T3 from the thyroid gland. The elevated levels of these thyroid hormones fail to downregulate the hypothalamic-pituitary-thyroid axis as they would in an individual without RTH, as shown in panel A (",
"    <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"     figure 1",
"    </a>",
"    ). As a result, these patients have high levels of T4 and T3, and normal or high levels of TSH. Because of this apparent dissociation between serum TH and TSH concentrations, the syndrome has been called \"inappropriate secretion of TSH\". However, TSH secretion is not really inappropriate because the response of the thyrotrophs to TH is reduced; to the contrary, it is compensatory and appropriate for the level of TH action mediated through the defective TR beta.",
"   </p>",
"   <p>",
"    The TSH secreted by these patients is rich in sialic acid and has increased bioactivity, as compared with normal TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/29\">",
"     29",
"    </a>",
"    ]. This explains why patients with RTH have goiter and high serum T4 and T3 concentrations even though their serum immunoreactive TSH concentrations are normal or only slightly high. The relationship between serum TSH and T4 concentrations in patients remains negative log-linear, but the slope of in serum",
"    <span class=\"nowrap\">",
"     TSH/free",
"    </span>",
"    T4 is lower, and the slope appears to be characteristic of the specific mutation involved [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effects on metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because increased TH secretion compensates for TH resistance, most patients with RTH are clinically euthyroid, although the completeness of compensation varies in different patients and in different tissues in the same patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the level of tissue responses does not always correlate with the serum T4 and T3 concentrations, probably because of discordance between the hormonal effects on the pituitary and other body tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/30\">",
"     30",
"    </a>",
"    ]. For example, patients with RTH have increased muscle-derived resting energy expenditure, -as a consequence of TH-mediated mitochondrial uncoupling [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of the decrease in T3-binding by the mutant TR beta is correlated with the clinical severity of RTH in most patients, which is usually determined by measuring the serum free T4 concentration needed to maintain normal TSH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/30\">",
"     30",
"    </a>",
"    ]. However, some patients have a mild phenotype despite having mutations that result in marked impairment of T3-binding. In these individuals, the mutations are located in domains of the TR that, in addition to binding T3, also alter receptor dimerization or association with other proteins that mediate the dominant-negative effect of the mutant receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of RTH is the paucity of symptoms and signs of thyroid dysfunction despite the presence of high serum T4 and T3 concentrations.",
"   </p>",
"   <p>",
"    Among all clinical findings, goiter is by far the most common (65 to 95 percent), followed by hyperactivity (33 to 68 percent) and tachycardia (33 to 75 percent) (",
"    <a class=\"graphic graphic_table graphicRef79670 \" href=\"UTD.htm?2/37/2652\">",
"     table 1",
"    </a>",
"    ). These abnormalities usually lead to evaluation of thyroid function. The subsequent finding of high serum T4 and T3 concentrations often results in the erroneous diagnosis of hyperthyroidism.",
"   </p>",
"   <p>",
"    Patients with RTH may have some symptoms or signs of hypothyroidism or hyperthyroidism, but these are variable and, when present, often inconstant (",
"    <a class=\"graphic graphic_table graphicRef79670 \" href=\"UTD.htm?2/37/2652\">",
"     table 1",
"    </a>",
"    ). If hypothyroidism is present, clinical features may include growth retardation, delayed bone maturation, learning disabilities, mental retardation, sensorineural deafness, and nystagmus. Patients with symptoms of hyperthyroidism may have tachycardia, hyperactivity, and increased basal metabolic rate. Overt hypothyroidism is more common in patients who, because of erroneous diagnosis of hyperthyroidism, received ablative or antithyroid treatment to reduce their TH level [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/4,14,32\">",
"     4,14,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a high prevalence of attention deficit hyperactivity disorder and learning disabilities in patients with RTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/4,32,37\">",
"     4,32,37",
"    </a>",
"    ]. Hearing loss may be due in part to recurrent ear infections, which are more common in the patients with RTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/32\">",
"     32",
"    </a>",
"    ]. However, sensorineural deafness is common among individuals with RTH due to TR beta gene deletion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/18\">",
"     18",
"    </a>",
"    ]. In mice, absence of TR beta-1 is sufficient to cause hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory findings and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the untreated subject, a high serum free T4 concentration and non-suppressed TSH are essential requirements for the diagnosis of RTH. Serum levels of T3 and rT3 are usually also high. The concentration of thyroglobulin (the protein within which T3 and T4 are synthesized and stored) tends to be high, reflecting the level of TSH-induced thyroid gland hyperactivity. The abnormalities should be confirmed by repeat measurements several weeks later. Other causes of reduced sensitivity to thyroid hormone (RSTH) are associated with low levels of at least one of these thyroid hormones (",
"    <a class=\"graphic graphic_table graphicRef50619 \" href=\"UTD.htm?31/61/32731\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Thyroid hormone cell transporter defect'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H33\">",
"     'Thyroid hormone metabolism defect'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All causes of high serum T4 and T3 concentrations in association with normal to high serum TSH levels should be considered in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef60910 \" href=\"UTD.htm?40/12/41164\">",
"     table 3",
"    </a>",
"    ). The following steps are appropriate to establish the diagnosis of RTH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To exclude abnormalities of TH binding in serum, including familial dysalbuminemic hyperthyroxinemia, hereditary and acquired thyroxine binding globulin excess, and transthyretin excess, measure serum free T4 and T3 by equilibrium dialysis. Normal values suggest a defect of TH binding in serum that could be confirmed by measurement of the specific protein or by genetic analysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=see_link\">",
"       \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To exclude a TSH-producing pituitary adenoma, measure the alpha subunit of TSH. A high ratio of alpha subunit to whole TSH is pathognomonic of TSH-secreting tumor. This disorder is associated with a similar TH profile to RTH but most, if not all, patients are hyperthyroid [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/39\">",
"       39",
"      </a>",
"      ]. This step is not necessary in patients with a familial pattern of RTH. Thus, evaluation of immediate family members (parents, siblings, children) by measurement of serum free T4 and TSH is effective in reaching a diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=see_link\">",
"       \"Thyrotropin (TSH)-secreting pituitary adenomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Determine if there are mutations in the TR beta gene by direct sequencing. Several commercial laboratories offer",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/2168?db=genetests\">",
"       sequencing of the TR beta gene",
"      </a>",
"      . This test provides a means to confirm the diagnosis, to obtain prenatal diagnosis, and to prevent inappropriate anti-thyroid treatment of patients with high serum levels of free TH.",
"     </li>",
"     <li>",
"      In patients without an identifiable TR beta gene mutation, dynamic testing is required to confirm or exclude the diagnosis of RTH. The response of TSH to TSH-releasing hormone is normal or exaggerated, depending on the baseline TSH level. The suppressive effect of administered TH on TSH, cholesterol and creatine kinase is blunted. Similarly, the stimulatory effect of TH on sex-hormone binding globulin and ferritin is attenuated (",
"      <a class=\"graphic graphic_figure graphicRef75538 \" href=\"UTD.htm?34/48/35587\">",
"       figure 3",
"      </a>",
"      ). The presence of the characteristic thyroid function tests in other family members distinguishes non-TR RTH from TSH-secreting pituitary adenomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no treatment that will correct the defect of TR beta function in subjects with RTH. Fortunately, in most patients, the hyposensitivity to TH seems to be adequately compensated by the increase in secretion of T4 and generation of T3. Thus, treatment is usually not needed. This is not the case in patients with limited thyroid reserve due to prior destructive therapy directed to the thyroid gland. These patients should be treated with a sufficient amount of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"     levothyroxine",
"    </a>",
"    to reduce their serum TSH concentrations to normal or near normal.",
"   </p>",
"   <p>",
"    In general, ablative treatment should be avoided. Large glands have been successfully treated by the administration of a single high dose of L-T3 given every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/40\">",
"     40",
"    </a>",
"    ]. Symptoms of thyrotoxicosis, more specifically tachycardia and tremor, respond to the administration of the beta adrenergic blocker,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"     atenolol",
"    </a>",
"    . Other treatments, such as triiodothyroacetic acid and D-thyroxine are not available in North America. Attention deficit hyperactivity disorder should be treated as indicated using drugs available for the treatment of this disorder independently from RTH.",
"   </p>",
"   <p>",
"    In some patients with RTH, several peripheral tissues may be relatively more resistant than the thyrotrophs. Thus, the compensation for the hormonal resistance in these tissues is incomplete and judicious administration of a dose of T4 higher than that needed to restore TSH secretion to normal may be indicated. The dose must be individually determined by assessing tissue responses. In children, this should be done by regular assessment of growth, bone maturation, and mental development.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"     Levothyroxine",
"    </a>",
"    should be given in incremental doses, and the basal metabolic rate, nitrogen balance, and serum sex hormone-binding globulin should be measured after treatment for four to six weeks before the dose is changed; bone age and growth should be followed on a longer-term basis. Development of a catabolic state is an indication of overtreatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of TH levels during pregnancy in a mother with RTH or a normal mother carrying a fetus with RTH is not straightforward. A pregnant woman with RTH is protected from adverse effects of her high TH levels, but fetal thyrotoxicosis may occur in offspring that do not carry the mutation.",
"   </p>",
"   <p>",
"    A retrospective study of a large family with RTH demonstrated that the adverse effect of thyroid hormone on the fetus was independent of that on the pregnant woman [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/41\">",
"     41",
"    </a>",
"    ]. The prevalence of early pregnancy loss was increased fivefold in affected mothers, but not in couples with an affected father and unaffected mother. Two-thirds of their infants carried the TR beta mutation, which suggests that nearly all miscarried fetuses had no mutation and thus, a normal response to TH. Furthermore, unaffected infants born to affected mothers had lower birth weights and suppressed serum TSH concentrations when compared to affected infants. These adverse pregnancy outcomes are similar to those for infants with excess thyroid hormone caused by gain-of-function TSH receptor mutations who are born prematurely and have low birth weights [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of pregnancies in mothers with RTH who are carrying unaffected fetuses may warrant judicious use of anti-thyroid medication, depending on the wellbeing of the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/43\">",
"     43",
"    </a>",
"    ]. In such mothers, free T4 should be maintained not higher than 20 percent above the upper limit of normal. This can be achieved by judicious use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    , taking care to avoid inducing hypothyroidism. There is no basis for regular treatment of normal mothers carrying affected fetuses unless the fetus is found to have a large goiter or be in distress, in which case the only treatment alternative is intraamniotic infusion of LT-4, although this has not been reported. Further studies are needed before general recommendations can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     THYROID HORMONE CELL TRANSPORTER DEFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monocarboxylate transporter 8 (MCT8) gene, also called SLC16A2, encodes a thyroid hormone (TH) transporter. This transporter appears to play an important role in the movement of thyroid hormone into the brain and, therefore, in the effect of thyroid hormone on brain development [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Mutations in the MCT8 gene cause an X-chromosome linked syndromic defect combining severe psychomotor deficiency and abnormal thyroid function tests. The early hallmarks are hypotonia and high serum T3 levels.",
"   </p>",
"   <p>",
"    TH is transported across cell membranes by a variety of transport proteins. These proteins belong to different families of solute carriers, organic anions, amino acids, and monocarboxylate transporters (MCT). It has been postulated that defects in transport proteins other than MCT8 also could cause reduced sensitivity to thyroid hormone (RSTH), but such mutations have not yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/46\">",
"     46",
"    </a>",
"    ]. Differences in cell distribution and kinetics, as well as transport of other ligands, provide each transport protein with a distinctive role in the cell-specific delivery of TH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/8\">",
"     8",
"    </a>",
"    ]. Presumably, defects in each transport protein would result in a distinct phenotype, the nature of which may be predicted by the generation of mice deficient in a specific transporter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prevalence and inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of a thyroid hormone cell transporter defect (THCTD) is not known. A sex-linked form of mental retardation with motor abnormalities was described in 1944 and subsequently named the Allan Herndon Dudley syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/47\">",
"     47",
"    </a>",
"    ]. Its etiology was recognized in 2004, when the same defect, associated with characteristic thyroid function test abnormalities, was found to be caused by MCT8 gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Since then, approximately 157 individuals belonging to 72 families with MCT8 gene defects were identified, suggesting that this syndrome is more common than initially suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/48-51\">",
"     48-51",
"    </a>",
"    ] (and personal observations). Spontaneous MCT8 gene mutations can be maintained in the population because carrier females are asymptomatic, thus no negative selection takes place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;MCT8 is a specific transporter of T4 and T3 into cells (",
"    <a class=\"graphic graphic_figure graphicRef70604 \" href=\"UTD.htm?39/4/40007\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/52\">",
"     52",
"    </a>",
"    ]. The clinical manifestations are probably caused by TH deprivation, particularly in the brain during embryonic and early postnatal life. Indeed, there appears to be a correlation between the degree of functional impairment of the mutant transporter and severity of the psychomotor retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/53\">",
"     53",
"    </a>",
"    ]. Several types of defects in the MCT8 gene can interfere with its function as a carrier protein, including reduced protein expression, impaired trafficking to plasma membrane, or reduced substrate affinity.",
"   </p>",
"   <p>",
"    MCT8 defects are characterized by an unusual mixed pattern of TH deprivation in some tissues and TH excess in others. Transgenic mice deficient in MCT8 have thyroid function test abnormalities similar to humans with mutations in this gene, and provide some understanding of the mechanisms responsible for the thyroid phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. In this animal model, tissue levels of T3 varied depending on redundancy in TH transmembrane transporters; the liver had high T3 concentrations, and brain T3 concentrations were low. The resulting increase in liver type 1 deiodinase and brain type 2 deiodinase enhances the generation of T3 and has a consumptive effect on T4. In addition, the impaired T3 uptake in some tissues such as the brain prevents its degradation by type 3 deiodinase. Another study in mice demonstrated that MCT8 defects also cause impaired TH secretion from the thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/13\">",
"     13",
"    </a>",
"    ], suggesting for the first time that MCT8 mediates the molecular mechanism of TH secretion, a process previously believed to be passive. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because MCT8 defects are x-linked, virtually all affected individuals are male; they present during infancy or early childhood with neurodevelopmental abnormalities. A single female patient with a phenotype identical to that of males had a de-novo balanced translocation at the MCT8 gene site [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/51\">",
"     51",
"    </a>",
"    ]. Early signs, manifesting in the first few weeks of life, are hypotonia and feeding difficulties. Though variable in severity, the clinical presentation is very similar, with consistent thyroid test abnormalities. Gestation and delivery are normal and affected newborns have normal length, weight, and head circumference.",
"   </p>",
"   <p>",
"    With advancing age, weight gain lags behind, leading to microcephaly, while linear growth proceeds normally. Although truncal hypotonia persists, there is progressive development of limb rigidity often resulting in spastic quadriplegia. Muscle mass is diminished and there is generalized muscle weakness with poor head control. Purposeless movements are common. Many infants have characteristic paroxysms of kinesigenic dyskinesias, consisting of body extension, opening of the mouth, and stretching or flexing of the limbs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/57\">",
"     57",
"    </a>",
"    ]. These paroxysms are usually triggered by somatosensory stimuli and last a few minutes or less. True seizures also can occur. Most affected children are never able to sit by themselves or walk, and have no speech.",
"   </p>",
"   <p>",
"    Affected individuals present stigmata of TH deficiency as well as excess. The psychomotor abnormalities are due to hormone deficiency, and the hypermetabolic state and difficulty to maintain weight are caused by hormone excess in some tissues. This coexistence of TH deficiency and excess in the same individual is due to cell-specific differences in the expression of the various TH transporters, as discussed above.",
"   </p>",
"   <p>",
"    Although early death has occurred in some families, some individuals live beyond the age of 70 years. Female carriers do not manifest any of the psychomotor abnormalities described above. However, intellectual delay and frank mental retardation have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/5,58\">",
"     5,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with MCT8 defects have characteristically high serum T3 and low rT3 concentrations, in contrast to the other two syndromes of reduced sensitivity to TH (",
"    <a class=\"graphic graphic_table graphicRef50619 \" href=\"UTD.htm?31/61/32731\">",
"     table 2",
"    </a>",
"    ). T4 has the tendency to be low and TSH levels are normal or slightly elevated. Heterozygous female carriers have serum TH concentrations intermediate between affected males and unaffected family members (",
"    <a class=\"graphic graphic_figure graphicRef65090 \" href=\"UTD.htm?35/63/36853\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by sequencing the MCT8 gene in the affected individuals.",
"   </p>",
"   <p>",
"    When brain magnetic resonance imaging (MRI) is obtained before the age of 2 or 3 years, delayed myelination is typically found [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/59\">",
"     59",
"    </a>",
"    ]. Otherwise, MRI may be normal or show atrophy of the cerebrum, thalamus, corpus callosum, and basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/48,50,60-62\">",
"     48,50,60-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current treatment options for patients with MCT8 gene mutations are limited to supportive measures, including the use of braces to prevent contractures. Diet is adjusted to prevent aspiration and dystonia is treated with anticholinergics, L-DOPA,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    . Drooling may respond to treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/4/43078?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/9/34960?source=see_link\">",
"     scopolamine",
"    </a>",
"    . Seizures are treated with standard anticonvulsants. &nbsp;",
"   </p>",
"   <p>",
"    Treatment of the low serum T4 concentration with physiological doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"     levothyroxine",
"    </a>",
"    has been ineffective, presumably because of the impaired uptake of the hormone in MCT8-dependent tissues. Treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    to reduce the amount of T3 generated, along with higher doses of levothyroxine, was effective in improving nutrition in one case [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/63\">",
"     63",
"    </a>",
"    ]. The use of TH analogues that may bypass the molecular defect by using alternative transporters has been studied in Mct8-deficient mice, and one of them, the 3,5-diiodothyropropionic acid (DITPA) is able to ameliorate the brain TH deficit in these mice without causing thyrotoxic effect in liver [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/64\">",
"     64",
"    </a>",
"    ]. The potential clinical utility of this analog in patients with MCT8 gene mutations is currently being investigated. Other treatment strategies are being tested in MCT8-deficient mice, including administration of levothyroxine together with propylthiouracil during pregnancy are being tested in Mct8-deficient mice.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24641328\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a family with a known history of an affected child and a known mutation of MCT8, male fetuses can be assessed in utero for the mutation. If the pregnancy with an affected male embryo is allowed to progress, treatment with high doses of TH can be considered, but further studies are needed to determine whether this treatment can prevent the neurologic sequelae of this condition. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     THYROID HORMONE METABOLISM DEFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired changes in thyroid hormone (TH) metabolism are common (eg, the \"low T3 syndrome\" of non-thyroidal illness) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/65\">",
"     65",
"    </a>",
"    ]. By contrast, the only known inherited defect of TH metabolism defect (THMD) involves the gene for selenocysteine insertion sequence-binding protein 2 (SECISBP2, in short SBP2), 1 of the 12 known genes involved in deiodinase synthesis and degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/7\">",
"     7",
"    </a>",
"    ]. The mutation produces a global deiodination defect that gives rise to a low T3, and high T4 and rT3. Defects in a specific deiodinase have not been identified in humans, but if they did occur, they would probably interfere with TH metabolism, with variable phenotypes as predicted by mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intracellular metabolism of thyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracellular iodothyronine metabolism satisfies the varying requirements of TH, which depend on tissue, cell type, and time. TH is activated and inactivated by site-specific monodeiodination to provide the proper amount of active hormone at its site of action. Deiodinases are selenoproteins that require a selenocysteine for their enzymatic function. Type 1 and 2 deiodinases (D1 and D2) catalyze the activation of TH by 5' deiodination that converts T4 to T3. Type 3 deiodinase (D3) inactivates T4 and T3 by 5-deiodination, leading to the generation of rT3 and T2, respectively.",
"   </p>",
"   <p>",
"    The SBP2 gene, located in chromosome 9, is expressed at a low level in all tissues and at a high level in testis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/67\">",
"     67",
"    </a>",
"    ]. Inactivating mutations in this gene prevent incorporation of selenocysteine moiety into the nascent selenoproteins, and thus alters the protein structure and enzymatic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prevalence and inheritances",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of inherited defects of TH metabolism is unknown. The first three mutations in the SBP2 gene were reported in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/7\">",
"     7",
"    </a>",
"    ]. Four more families were found subsequently [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. The inheritance is recessive, homozygous, or compound heterozygous. Two of the families are of African origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although these defects cause generalized deficiency of selenoproteins, the phenotype of abnormal thyroid tests and early growth delay reported in the initial families was relatively mild, due to partial SBP2 deficiency and preferential preservation of certain selenoproteins over other",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    -requiring functions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/68,69,72\">",
"     68,69,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A broader and more complex phenotype was brought to light by the subsequent identification of three new cases from different families with SBP2 gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. These mutations caused a severe SBP2 deficiency resulting in reduced synthesis of most of the 25 known human selenoproteins, which alter diverse biological processes. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Clinical features'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with partial SBP2 deficiency have come to medical attention during childhood because of short stature and delayed bone age. These features prompted thyroid function testing, leading to the identification of thyroid abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/7\">",
"     7",
"    </a>",
"    ]. Pregnancy and birth were normal but the neonatal screen in one of the children showed an elevated TSH level with high normal T4.",
"   </p>",
"   <p>",
"    In patients with more severe SBP2 deficiency, which reduces synthesis of most of the 25 human selenoproteins, a wider variety of abnormalities may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Azoospermia",
"     </li>",
"     <li>",
"      Axial muscular dystrophy, with impaired motor coordination",
"     </li>",
"     <li>",
"      Intellectual disability (mental retardation)",
"     </li>",
"     <li>",
"      Hearing impairment",
"     </li>",
"     <li>",
"      Photosensitivity and susceptibility to ultraviolet radiation-induced oxidative damage",
"     </li>",
"     <li>",
"      Abnormal immune cell function (impaired T lymphocyte proliferation, abnormal mononuclear cell cytokine secretion [excess IL-6 and TNF&alpha;; reduced IFN&gamma;, and telomere shortening)",
"     </li>",
"     <li>",
"      Enhanced systemic and cellular insulin sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/70\">",
"       70",
"      </a>",
"      ]. This was associated with raised reactive oxygen species (ROS), similar to findings in antioxidant selenoenzyme (GPx1) knockout mice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some of these patients, multiple tissues and organs show damage mediated by ROS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/70\">",
"     70",
"    </a>",
"    ], and it is conceivable that other pathologies linked to oxidative damage such as neoplasia, neurodegeneration, premature ageing, may manifest with time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical laboratory findings are high T4, low T3, high rT3, and normal or slightly elevated serum TSH. A comparison to the other two syndromes of reduced sensitivity to thyroid hormone (RSTH) is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef50619 \" href=\"UTD.htm?31/61/32731\">",
"     table 2",
"    </a>",
"    ). No other hormonal abnormalities have been detected and serum IGF1 concentrations are normal despite delayed growth. Affected individuals require larger doses of L-T4 but not L-T3 to suppress their serum TSH concentration.",
"   </p>",
"   <p>",
"    Serum concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , selenoprotein P and other selenoproteins are reduced. Skin fibroblasts have low selenoprotein deiodinase D2 enzymatic activity but normal mRNA content, reflecting a defect in selenoenzyme synthesis.",
"   </p>",
"   <p>",
"    Detailed evaluation of two cases with severe SBP2 deficiency demonstrated deficiencies in multiple selenoproteins: lack of testis-enriched selenoproteins resulting in failure of the latter stages of spermatogenesis and azoospermia; selenoprotein N (SEPN) like myopathy resulting in axial muscular dystrophy; cutaneous deficiencies of antioxidant selenoenzymes causing increased cellular ROS; and reduced selenoproteins in peripheral blood cells resulting in immune deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/70\">",
"     70",
"    </a>",
"    ]. In addition, deficiencies of other selenoproteins with unknown function SELH, SELT, SELW, SELI were also found and their consequences are not yet known. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific treatment is available. In one study, administration of up to 400 mcg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    normalized the serum selenium concentration but had no effect on selenoprotein deiodinase D2 activity and glutathione peroxidase concentration, and failed to correct the abnormalities of serum iodothyronine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/37/1626/abstract/73\">",
"     73",
"    </a>",
"    ]. Delayed linear growth can be corrected with L-T3. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced sensitivity to thyroid hormone (RSTH) is used to describe any process that impairs the effectiveness of thyroid hormone (TH), and can be caused by each of the following mechanisms (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms of resistance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Resistance to thyroid hormone (RTH) [caused by TH receptor defects or unknown etiology]",
"     </li>",
"     <li>",
"      Thyroid hormone cell transporter defect (THCTD)",
"     </li>",
"     <li>",
"      Thyroid hormone metabolism defect (THMD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These disorders can be distinguished by their characteristic abnormalities of thyroid function. In each disorder, mutations in a single gene are responsible for most or all identified cases (",
"      <a class=\"graphic graphic_table graphicRef50619 \" href=\"UTD.htm?31/61/32731\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Resistance to thyroid hormone",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RTH is an inherited syndrome characterized by reduced responsiveness of target tissues to thyroid hormone. The disorder is characterized by high serum concentrations of free T4 and usually also free T3, accompanied by normal or slightly high serum TSH concentration (",
"      <a class=\"graphic graphic_table graphicRef50619 \" href=\"UTD.htm?31/61/32731\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Resistance to thyroid hormone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hallmark of RTH is the paucity of symptoms and signs of thyroid dysfunction despite the presence of high serum T4 and T3 concentrations. Clinical features include goiter, hyperactivity, and tachycardia (",
"      <a class=\"graphic graphic_table graphicRef79670 \" href=\"UTD.htm?2/37/2652\">",
"       table 1",
"      </a>",
"      ). The clinical disease is usually mild because the hyposensitivity to TH is adequately compensated by the increase in secretion of T4 and generation of T3. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Resistance to thyroid hormone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In approximately 85 percent of cases, RTH is due to mutations in the TH receptor beta gene. In approximately 15 percent of cases, RTH is caused by yet undetermined genetic abnormalities. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Thyroid hormone receptor mutations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'NonTR-RTH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of RTH depends on characteristic elevations in TH and exclusion of other causes of hyperthyroxinemia (",
"      <a class=\"graphic graphic_table graphicRef60910 \" href=\"UTD.htm?40/12/41164\">",
"       table 3",
"      </a>",
"      ). When RTH is suspected, the diagnosis should be confirmed by direct sequencing of the TR beta gene to identify mutations. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory findings and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Thyroid hormone cell transporter defect",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      THCTD cause reduced intracellular levels of thyroid hormones because of inadequate transport of thyroid hormone into target cells. The only identified THCTD is an X-linked mutation in the monocarboxylate transporter (MCT) 8 gene. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Thyroid hormone cell transporter defect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical laboratory findings of MCT8 deficiency are high serum T3 and low rT3 concentrations; this pattern is distinct from other causes of THR (",
"      <a class=\"graphic graphic_table graphicRef50619 \" href=\"UTD.htm?31/61/32731\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The early hallmarks of MCT8 defects are hypotonia and high serum T3 levels in male infants. Affected individuals have stigmata of TH deficiency, including severe neurodevelopmental abnormalities, as well as TH excess, manifesting as inability to gain weight independent of nutrition. Carrier females have intermediate TH concentrations, and are asymptomatic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Thyroid hormone metabolism defect",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      THMD are inherited defects of intracellular thyroid hormone metabolism. The only known THMD is a defect of selenocysteine insertion sequence-binding protein 2 (SECISBP2, or SBP2). Mutations in SBP2 gene interfere with selenoprotein synthesis. Only a few individuals with this defect have been described. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Thyroid hormone metabolism defect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical laboratory findings are high T4, low T3, high rT3, and normal or slightly elevated serum TSH (",
"      <a class=\"graphic graphic_table graphicRef50619 \" href=\"UTD.htm?31/61/32731\">",
"       table 2",
"      </a>",
"      ), decreased serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      and decreased selenoprotein levels and activity in serum and tissues. The clinical phenotype is complex; affected individuals may have delayed growth and puberty, and in severe cases failure to thrive, mental retardation, infertility, myopathy, hearing impairment, photosensitivity, and immune deficits. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/1\">",
"      Refetoff S, DeWind LT, DeGroot LJ. Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab 1967; 27:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/2\">",
"      Sakurai A, Takeda K, Ain K, et al. Generalized resistance to thyroid hormone associated with a mutation in the ligand-binding domain of the human thyroid hormone receptor beta. Proc Natl Acad Sci U S A 1989; 86:8977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/3\">",
"      Usala SJ, Tennyson GE, Bale AE, et al. A base mutation of the C-erbA beta thyroid hormone receptor in a kindred with generalized thyroid hormone resistance. Molecular heterogeneity in two other kindreds. J Clin Invest 1990; 85:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/4\">",
"      Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993; 14:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/5\">",
"      Dumitrescu AM, Liao XH, Best TB, et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 2004; 74:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/6\">",
"      Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 2004; 364:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/7\">",
"      Dumitrescu AM, Liao XH, Abdullah MS, et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nat Genet 2005; 37:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/8\">",
"      Friesema EC, Jansen J, Milici C, Visser TJ. Thyroid hormone transporters. Vitam Horm 2005; 70:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/9\">",
"      Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002; 23:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/10\">",
"      Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 2003; 213:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/11\">",
"      Zhang J, Lazar MA. The mechanism of action of thyroid hormones. Annu Rev Physiol 2000; 62:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/12\">",
"      Yen PM, Ando S, Feng X, et al. Thyroid hormone action at the cellular, genomic and target gene levels. Mol Cell Endocrinol 2006; 246:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/13\">",
"      Di Cosmo C, Liao XH, Dumitrescu AM, et al. Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion. J Clin Invest 2010; 120:3377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/14\">",
"      Beck-Peccoz P, Chatterjee VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid 1994; 4:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/15\">",
"      Koenig RJ. Thyroid hormone receptor coactivators and corepressors. Thyroid 1998; 8:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/16\">",
"      Lafranchi SH, Snyder DB, Sesser DE, et al. Follow-up of newborns with elevated screening T4 concentrations. J Pediatr 2003; 143:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/17\">",
"      Refetoff S, Dumitrescu AM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab 2007; 21:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/18\">",
"      Takeda K, Sakurai A, DeGroot LJ, Refetoff S. Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene. J Clin Endocrinol Metab 1992; 74:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/19\">",
"      Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 2001; 86:5572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/20\">",
"      Flamant F, Samarut J. Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. Trends Endocrinol Metab 2003; 14:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/21\">",
"      Wikstr&ouml;m L, Johansson C, Salt&oacute; C, et al. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J 1998; 17:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/22\">",
"      Weiss RE, Murata Y, Cua K, et al. Thyroid hormone action on liver, heart, and energy expenditure in thyroid hormone receptor beta-deficient mice. Endocrinology 1998; 139:4945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/23\">",
"      Weiss RE, Marcocci C, Bruno-Bossio G, Refetoff S. Multiple genetic factors in the heterogeneity of thyroid hormone resistance. J Clin Endocrinol Metab 1993; 76:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/24\">",
"      Bochukova E, Schoenmakers N, Agostini M, et al. A mutation in the thyroid hormone receptor alpha gene. N Engl J Med 2012; 366:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/25\">",
"      van Mullem A, van Heerebeek R, Chrysis D, et al. Clinical phenotype and mutant TR&alpha;1. N Engl J Med 2012; 366:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/26\">",
"      Weiss RE, Hayashi Y, Nagaya T, et al. Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective cofactor. J Clin Endocrinol Metab 1996; 81:4196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/27\">",
"      Reutrakul S, Sadow PM, Pannain S, et al. Search for abnormalities of nuclear corepressors, coactivators, and a coregulator in families with resistance to thyroid hormone without mutations in thyroid hormone receptor beta or alpha genes. J Clin Endocrinol Metab 2000; 85:3609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/28\">",
"      Barkoff MS, Kocherginsky M, Anselmo J, et al. Autoimmunity in patients with resistance to thyroid hormone. J Clin Endocrinol Metab 2010; 95:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/29\">",
"      Persani L, Borgato S, Romoli R, et al. Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. J Clin Endocrinol Metab 1998; 83:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/30\">",
"      Hayashi Y, Weiss RE, Sarne DH, et al. Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-beta receptors? J Clin Endocrinol Metab 1995; 80:3246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/31\">",
"      Ercan-Fang S, Schwartz HL, Mariash CN, Oppenheimer JH. Quantitative assessment of pituitary resistance to thyroid hormone from plots of the logarithm of thyrotropin versus serum free thyroxine index. J Clin Endocrinol Metab 2000; 85:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/32\">",
"      Brucker-Davis F, Skarulis MC, Grace MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 1995; 123:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/33\">",
"      Mitchell CS, Savage DB, Dufour S, et al. Resistance to thyroid hormone is associated with raised energy expenditure, muscle mitochondrial uncoupling, and hyperphagia. J Clin Invest 2010; 120:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/34\">",
"      Yagi H, Pohlenz J, Hayashi Y, et al. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity. J Clin Endocrinol Metab 1997; 82:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/35\">",
"      Yoh SM, Chatterjee VK, Privalsky ML. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol 1997; 11:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/36\">",
"      Tagami T, Gu WX, Peairs PT, et al. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators. Mol Endocrinol 1998; 12:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/37\">",
"      Hauser P, Zametkin AJ, Martinez P, et al. Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. N Engl J Med 1993; 328:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/38\">",
"      Abel ED, Boers ME, Pazos-Moura C, et al. Divergent roles for thyroid hormone receptor beta isoforms in the endocrine axis and auditory system. J Clin Invest 1999; 104:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/39\">",
"      Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996; 17:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/40\">",
"      Anselmo J, Refetoff S. Regression of a large goiter in a patient with resistance to thyroid hormone by every other day treatment with triiodothyronine. Thyroid 2004; 14:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/41\">",
"      Anselmo J, Cao D, Karrison T, et al. Fetal loss associated with excess thyroid hormone exposure. JAMA 2004; 292:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/42\">",
"      Vaidya B, Campbell V, Tripp JH, et al. Premature birth and low birth weight associated with nonautoimmune hyperthyroidism due to an activating thyrotropin receptor gene mutation. Clin Endocrinol (Oxf) 2004; 60:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/43\">",
"      Weiss RE, Dumitrescu A, Refetoff S. Approach to the patient with resistance to thyroid hormone and pregnancy. J Clin Endocrinol Metab 2010; 95:3094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/44\">",
"      Heuer H, Visser TJ. Minireview: Pathophysiological importance of thyroid hormone transporters. Endocrinology 2009; 150:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/45\">",
"      Ceballos A, Belinchon MM, Sanchez-Mendoza E, et al. Importance of monocarboxylate transporter 8 for the blood-brain barrier-dependent availability of 3,5,3'-triiodo-L-thyronine. Endocrinology 2009; 150:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/46\">",
"      Hennemann G, Docter R, Friesema EC, et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev 2001; 22:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/47\">",
"      Allan W, Herndon CN, Dudley FC. Some examples of the inheritance of mental deficiency: apparently sex-linked idiocy and microcephaly. Am J Ment Defic 1944; 48:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/48\">",
"      Kakinuma H, Itoh M, Takahashi H. A novel mutation in the monocarboxylate transporter 8 gene in a boy with putamen lesions and low free T4 levels in cerebrospinal fluid. J Pediatr 2005; 147:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/49\">",
"      Visser WE, Friesema EC, Jansen J, Visser TJ. Thyroid hormone transport in and out of cells. Trends Endocrinol Metab 2008; 19:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/50\">",
"      Papadimitriou A, Dumitrescu AM, Papavasiliou A, et al. A novel monocarboxylate transporter 8 gene mutation as a cause of severe neonatal hypotonia and developmental delay. Pediatrics 2008; 121:e199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/51\">",
"      Frints SG, Lenzner S, Bauters M, et al. MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression. Eur J Hum Genet 2008; 16:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/52\">",
"      Friesema EC, Ganguly S, Abdalla A, et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003; 278:40128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/53\">",
"      Jansen J, Friesema EC, Kester MH, et al. Genotype-phenotype relationship in patients with mutations in thyroid hormone transporter MCT8. Endocrinology 2008; 149:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/54\">",
"      Dumitrescu AM, Liao XH, Weiss RE, et al. Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (mct) 8-deficient mice. Endocrinology 2006; 147:4036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/55\">",
"      Trajkovic M, Visser TJ, Mittag J, et al. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest 2007; 117:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/56\">",
"      Bernal J. Role of monocarboxylate anion transporter 8 (MCT8) in thyroid hormone transport: Answers from mice. Endocrinology 2006; 147:4034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/57\">",
"      Brockmann K, Dumitrescu AM, Best TT, et al. X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene. J Neurol 2005; 252:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/58\">",
"      Herzovich V, Vaiani E, Marino R, et al. Unexpected peripheral markers of thyroid function in a patient with a novel mutation of the MCT8 thyroid hormone transporter gene. Horm Res 2007; 67:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/59\">",
"      Gika AD, Siddiqui A, Hulse AJ, et al. White matter abnormalities and dystonic motor disorder associated with mutations in the SLC16A2 gene. Dev Med Child Neurol 2010; 52:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/60\">",
"      Holden KR, Zu&ntilde;iga OF, May MM, et al. X-linked MCT8 gene mutations: characterization of the pediatric neurologic phenotype. J Child Neurol 2005; 20:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/61\">",
"      Namba N, Etani Y, Kitaoka T, et al. Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporter. Eur J Pediatr 2008; 167:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/62\">",
"      Vaurs-Barri&egrave;re C, Deville M, Sarret C, et al. Pelizaeus-Merzbacher-Like disease presentation of MCT8 mutated male subjects. Ann Neurol 2009; 65:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/63\">",
"      W&eacute;meau JL, Pigeyre M, Proust-Lemoine E, et al. Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8. J Clin Endocrinol Metab 2008; 93:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/64\">",
"      Di Cosmo C, Liao XH, Dumitrescu AM, et al. A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology 2009; 150:4450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/65\">",
"      Koenig RJ. Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 2005; 15:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/66\">",
"      Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006; 116:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/67\">",
"      Lescure A, Allmang C, Yamada K, et al. cDNA cloning, expression pattern and RNA binding analysis of human selenocysteine insertion sequence (SECIS) binding protein 2. Gene 2002; 291:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/68\">",
"      Copeland PR. Regulation of gene expression by stop codon recoding: selenocysteine. Gene 2003; 312:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/69\">",
"      Di Cosmo C, McLellan N, Liao XH, et al. Clinical and molecular characterization of a novel selenocysteine insertion sequence-binding protein 2 (SBP2) gene mutation (R128X). J Clin Endocrinol Metab 2009; 94:4003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/70\">",
"      Schoenmakers E, Agostini M, Mitchell C, et al. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest 2010; 120:4220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/71\">",
"      Azevedo MF, Barra GB, Naves LA, et al. Selenoprotein-related disease in a young girl caused by nonsense mutations in the SBP2 gene. J Clin Endocrinol Metab 2010; 95:4066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/72\">",
"      K&ouml;hrle J. Selenium and the control of thyroid hormone metabolism. Thyroid 2005; 15:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/37/1626/abstract/73\">",
"      Schomburg L, Dumitrescu AM, Liao XH, et al. Selenium supplementation fails to correct the selenoprotein synthesis defect in subjects with SBP2 gene mutations. Thyroid 2009; 19:277.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5827 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1626=[""].join("\n");
var outline_f1_37_1626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL THYROID HORMONE PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RESISTANCE TO THYROID HORMONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thyroid hormone action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prevalence and inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thyroid hormone receptor mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - NonTR-RTH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24641580\">",
"      - Associated abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Effects on the hypothalamic-pituitary-thyroid axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effects on metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory findings and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      THYROID HORMONE CELL TRANSPORTER DEFECT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prevalence and inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24641328\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      THYROID HORMONE METABOLISM DEFECT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intracellular metabolism of thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prevalence and inheritances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Resistance to thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Thyroid hormone cell transporter defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Thyroid hormone metabolism defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5827\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5827|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/4/40007\" title=\"figure 1\">",
"      TH physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/2/6180\" title=\"figure 2\">",
"      TR beta molecule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/48/35587\" title=\"figure 3\">",
"      RTH hormonal response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/63/36853\" title=\"figure 4\">",
"      Hormones in THCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5827|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/37/2652\" title=\"table 1\">",
"      Symptoms RTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/61/32731\" title=\"table 2\">",
"      Reduced sensit TH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/12/41164\" title=\"table 3\">",
"      Causes high T4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=related_link\">",
"      Resistance to thyrotropin and thyrotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10200?source=related_link\">",
"      Thyroid hormone action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=related_link\">",
"      Thyrotropin (TSH)-secreting pituitary adenomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_37_1627="Management of premenopausal osteoporosis";
var content_f1_37_1627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of premenopausal osteoporosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Calcium 1000 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D 600 IU daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight bearing exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Changes in habits (avoidance of smoking, excess alcohol, poor nutrition)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment of secondary causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharmacologic treatment in selected cases",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carolyn Becker, MD and Adi Cohen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1627=[""].join("\n");
var outline_f1_37_1627=null;
var title_f1_37_1628="Pre-liver transplant evaluation";
var content_f1_37_1628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pre-liver transplantion evaluation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiopulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EKG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contrast enhanced bubble echocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac stress test (adenosine, persantine, dobutamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest X-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary function test w/DLCO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial blood gas on room air",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cancer Surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal computerized tomography or magnetic resonance imaging for hepatocellular carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAP smear/mammogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychosocial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Social work evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient education seminars",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcoholics Anonymous or drug rehabilitation (if indicated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doppler ultrasound to assess vasculature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PPD within last year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone density",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Labs:",
"    </strong>",
"    ABO blood type, Hepatic Function Panel, CBC with diff, PT/INR&lt; AFP, CMV, EBV, Varicella, RPR, Hepatitis Serologies, HIV antibody, PSA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lorna Dove, MD, MPH and Robert Brown, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1628=[""].join("\n");
var outline_f1_37_1628=null;
var title_f1_37_1629="Nutrition risk chronic disease";
var content_f1_37_1629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutritional risk factors associated with selected childhood conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight",
"       </td>",
"       <td class=\"subtitle1\">",
"        Height",
"       </td>",
"       <td class=\"subtitle1\">",
"        Energy needs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Feeding problems",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autism",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic lung disease",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral palsy",
"       </td>",
"       <td>",
"        increased or decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        increased or decreased",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Down syndrome",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal alcohol syndrome",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital heart disease",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV/AIDS",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prader-Willi syndrome",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prematurity",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        increased",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizure disorder",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spina bifida",
"       </td>",
"       <td>",
"        increased or decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        decreased",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May be present.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Baer MT, Harris A. Pediatric nutrition assessment: identifying children at risk. J Am Diet Assoc 1997; 97 (10 Suppl 2):S107.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1629=[""].join("\n");
var outline_f1_37_1629=null;
var title_f1_37_1630="Prognostic factors thy ca";
var content_f1_37_1630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used risk factors for stratification of risk of death from disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Parameters",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        EORTC",
"        <sup>",
"         [1]",
"        </sup>",
"       </p>",
"       <p>",
"        (1979)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        AGES",
"        <sup>",
"         [2]",
"        </sup>",
"       </p>",
"       <p>",
"        (1987)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        AMES",
"        <sup>",
"         [3]",
"        </sup>",
"       </p>",
"       <p>",
"        (1988)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        MACIS",
"        <sup>",
"         [4]",
"        </sup>",
"       </p>",
"       <p>",
"        (1993)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        OSU",
"        <sup>",
"         [5]",
"        </sup>",
"       </p>",
"       <p>",
"        (1994)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        MSKCC",
"        <sup>",
"         [6]",
"        </sup>",
"       </p>",
"       <p>",
"        (1995)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        NTCTCS",
"        <sup>",
"         [7]",
"        </sup>",
"       </p>",
"       <p>",
"        (1998)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        TNM",
"        <sup>",
"         [8]",
"        </sup>",
"       </p>",
"       <p>",
"        (2010)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Patient factors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Age",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gender",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Tumor factors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Size of primary tumor",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Multicentricity",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tumor grade",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Extrathyroidal extension",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lymph node involvement",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Distant metastasis",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Operative factors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Completeness of resection",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    X: variable used in defining risk group.",
"    <br>",
"     -: variable not used.",
"     <div class=\"footnotes\">",
"      AGES: patient age, histologic grade of the tumor, tumor extent (extrathyroidal invasion or distant metastases), and size of the primary tumor; AMES: patient age, presence of distant metastases, extent and size of the primary tumor; EORTC: European Organization for Research on Treatment of Cancer; MACIS: metastasis, patient age, completeness of resection, local invasion, and tumor size; MSKCC: Memorial Sloan-Kettering Cancer Center; NTCTCS: National Thyroid Cancer Treatment Cooperative Study; OSU: Ohio State University; TNM: American Joint Committee on Cancer staging system of tumor size, nodal metastases (N), and distant metastases (M).",
"     </div>",
"     <div class=\"reference\">",
"      1. Byar, DP, Green, SB, Dor, P, et al. A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15(8):1033-41.",
"      <br>",
"       2. Hay, ID, Grant, CS, Taylor, WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papilliary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102(6):1088-95.",
"       <br>",
"        3. Cady, B, Rossi, R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104(6):947-53.",
"        <br>",
"         4. Hay, ID, Bergstralh, EJ, Goellner, JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114(6):1050-7 [discussion: 1057-8].",
"         <br>",
"          5. Mazzaferri, EL, Jhiang, SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97(5):418-28.",
"          <br>",
"           6. Shaha, AR, Loree, TR, Shah, JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118(6):1131-6 [discussion:1136-8].",
"           <br>",
"            7. Sherman, SI, Brierley, JD, Sperling, M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998; 83(5):1012-21.",
"            <br>",
"             8. AJCC Cancer Staging Manual. 7th edition. New York: Springer-Verlag; 2010.",
"             <br>",
"              Reproduced by permission from:",
"              <br>",
"               Cancer Control: Journal of the Moffitt Cancer Center. Dean, DS, Hay, ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000; 7(3)229-239. Copyright &copy;2000.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1630=[""].join("\n");
var outline_f1_37_1630=null;
var title_f1_37_1631="Low-fat low-sugar guide A";
var content_f1_37_1631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67313%7EPEDS%2F81884%7EPEDS%2F62244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67313%7EPEDS%2F81884%7EPEDS%2F62244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for maintaining a healthy weight: Low-fat, low-sugar eating guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Food to choose more often",
"       </td>",
"       <td class=\"subtitle1\">",
"        Food to limit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breads, cereals, starches and starchy vegetables",
"       </td>",
"       <td>",
"        Barley, bulgur, buckwheat (kasha); whole grain breads, bagels, English muffins, hamburger buns, rolls, tortillas, crackers, cereals, pancakes, and waffles; brown rice, whole wheat pasta, whole wheat couscous, unflavored oatmeal, winter squash, sweet potatoes, corn, corn tortillas",
"       </td>",
"       <td>",
"        Biscuits; store brought muffins, croissants, sweet rolls, Danish, and donuts; sugar coated cereals, crackers made with saturated fats; pasta and rice dishes prepared in a butter cream sauce; baked, fried, mashed or scalloped potatoes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetables",
"       </td>",
"       <td>",
"        Any fresh or frozen vegetable such as artichoke and artichoke hearts, asparagus, beans (green, wax, Italian), bean sprouts, beets, broccoli, brussel sprouts, cabbage, carrots, cauliflower, celery, cucumber, eggplant, green onions, greens (collard, kale, mustard, turnip), mushrooms, okra, onions, pea pods, peppers, radishes, salad greens (endive, escarole, lettuce, romaine, spinach), sauerkraut, spinach, summer squash, tomatoes and tomato sauce, vegetable juices, water chestnuts, watercress, zucchini",
"       </td>",
"       <td>",
"        Any vegetables prepared in butter, cream, or cheese sauce; fried vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruits",
"       </td>",
"       <td>",
"        Whole fresh and frozen fruits such as apple, banana, blueberries, cantaloupe, cherries, grapefruit, grapes, honeydew melon, kiwi, mango, orange, peach, pear, pineapple, plums, and strawberries",
"       </td>",
"       <td>",
"        Canned fruit, fruit juices, dried fruit and fried fruits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meat, poultry, fish, dried beans, eggs",
"       </td>",
"       <td>",
"        Fish, shellfish, skinned white-meat chicken and turkey, beans, peas, lentils, egg substitutes, egg whites, soybeans, and tofu",
"       </td>",
"       <td>",
"        Regular beef, pork, lamb, veal, and luncheon meats; fried chicken and fish, eggs, sausage, hot dogs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milk, yogurt and cheese",
"       </td>",
"       <td>",
"        Skim and 1 percent milk, plain nonfat yogurt, nonfat yogurt sweetened with aspartame or nonnutritive sweetener; fat-free or low-fat cheese and cottage cheese",
"       </td>",
"       <td>",
"        2 percent and whole milk, 1 percent and whole chocolate milk, goat's milk, kefir, low-fat yogurt (plain or fruit flavored), custard-style yogurt, regular cheese and cottage cheese",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for maintaining a healthy weight: Low-fat, low-sugar eating guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Food to choose more often",
"       </td>",
"       <td class=\"subtitle1\">",
"        Food to limit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fats",
"       </td>",
"       <td>",
"        Almonds, avocado, canola oil; fat-free or reduced-fat margarine, mayonnaise and salad dressings; olives, olive oil, peanut butter, peanuts, sunflower seeds, walnuts",
"       </td>",
"       <td>",
"        Bacon, butter, chitterlings, coconut; cream (half and half, whipped cream), cream cheese, saturated fats such as coconut, palm and palm kernel oils; shortening or lard, sour cream",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweets",
"       </td>",
"       <td>",
"        Sugar substitutes such as Equal, Sweet 'n Low, or Splenda; light or sugar-free syrups, light or low-sugar jams and jellies; sugar-free gelatin; sugar-free Popsicles",
"       </td>",
"       <td>",
"        Candy, sugar, syrup, honey, jam, jelly, gelatin, Popsicles and fruit juice bars, fruit snacks and fruit leather",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beverages",
"       </td>",
"       <td>",
"        Water, diet sodas, sugar-free drink mixes, sugar-free flavored water, unsweetened iced tea, coffee",
"       </td>",
"       <td>",
"        Regular sodas, fruit juices, sports drinks, drink mixes, sweet tea, and flavored coffee beverages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        Catsup, mustard, pickles, salsa, spices, lemon juice",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Snacks (in very limited amounts)",
"       </td>",
"       <td>",
"        Low-fat popcorn, pretzels, baked or low-fat chips, rice cakes, graham crackers, granola bars, fat-free and low-fat frozen yogurt, fat-free fudge bars, homemade fruit smoothies",
"       </td>",
"       <td>",
"        Chips, buttered popcorn; store bought cakes, cookies and pies; chocolate, sherbet, ice cream, pudding",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Low-fat, low-sugar eating guidelines sample menus*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Breakfast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 slices whole-grain bread or frozen waffles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 teaspoons almond butter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk or yogurt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small banana",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lunch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Turkey sandwich (2 ounces turkey breast on a whole- grain bread or roll)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup green grapes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup baby carrots, jicama and bell pepper strips",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 tablespoons fat-free ranch dressing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk or fat-free, reduced-calorie yogurt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bottled water or diet soda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dinner",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3-4 ounces grilled salmon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2/3 cup steamed/boiled brown rice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 cups mixed salad greens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 tablespoon balsamic vinegar with 2 teaspoons olive oil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup steamed green beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water with lemon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Snack",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fruit smoothie",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            (1 cup skim milk, 1 cup frozen fruit such as peaches or mixed berries)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3 cups low-fat popcorn",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 ounce peanuts",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Breakfast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breakfast taco (small whole-wheat flour tortilla, 1/2 cup egg substitute, 1 ounce reduced-fat cheese, 2 tablespoons salsa)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small orange",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lunch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 ounces water-packed tuna mixed with 1 tablespoon light mayonnaise, chopped celery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            10 whole grain crackers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small apple",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk or fat-free,",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            reduced-calorie yogurt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water or diet soda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dinner",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup vegetable soup (carrots, celery, onions, tomato)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2-3 ounces grilled chicken breast (skinless)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup black beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup steamed/boiled brown rice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 corn tortillas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup lettuce and tomato salad with 1/8 avocado slice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water or unsweetened iced tea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Snack",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 mango",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup fat-free, reduced-calorie yogurt with 1 ounce almond slivers",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Breakfast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup old-fashioned oatmeal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small pear",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lunch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peanut butter sandwich on whole wheat bread",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Apple",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup carrot and celery sticks",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 tablespoons light ranch dressing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk or fat-free, reduced-calorie yogurt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water or diet soda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dinner",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3-4 ounces baked barbeque chicken breast (skinless)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup mashed sweet potato",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup steamed cabbage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup steamed turnip greens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small whole grain roll with 1 tablespoon light margarine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water or unsweetened iced tea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Snack",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6 cups low-fat popcorn",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diet soda or sugar-free Kool-Aid",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All meals are prepared without added fat.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_37_1631=[""].join("\n");
var outline_f1_37_1631=null;
